

---

# All new STI episodes seen at GUM clinics in the UK: 1997 - 2006



Data is represented by country, gender and sexual orientation.

---

## Notes on using these tables:

Numbers of diagnoses are adjusted for missing clinic data

## Data Source:

England: GUM clinic KC60 returns  
Wales: GUM clinic KC60 returns  
Northern Ireland: GUM clinic KC60 returns  
Scotland: GUM clinic ISD(D)5 returns from 31/03/2004 and STISS returns from 01/04/2004

## Data Supplied by:

Health Protection Agency, Centre for Infections  
Communicable Disease Surveillance Centre Wales  
Communicable Disease Surveillance Centre Northern Ireland  
Regional Information Branch, Department of Health, Social Services and Public Safety (DHSS&PS Northern Ireland)  
ISD Scotland, Information Services, NHS National Services Scotland

## Definitions of selected data totals:

Total new STI diagnoses: refer to 'Code Groups' for included KC60 conditions  
Total other STI diagnoses: refer to 'Code Groups' for included KC60 conditions  
Total other GUM clinic diagnoses: refer to 'Code Groups' for included KC60 conditions  
Total services provided: refer to 'Code Groups' for included KC60 conditions

---

## Data prepared by:

HIV and Sexually Transmitted Infections Department  
Health Protection Agency  
Centre for Infections  
61 Colindale Avenue  
London  
NW9 5EQ

Tel. 020-8200-6868  
Email: [hiv/sti@hpa.org.uk](mailto:hiv/sti@hpa.org.uk)  
Website: [www.hpa.org.uk](http://www.hpa.org.uk)

---

<b>Data tables</b>	<b>Page</b>
United Kingdom	3
England	9
Wales	15
Northern Ireland	21
Scotland	27
Code Groups	40

---

## **Further Information**

### **England**

Data on selected diagnoses, 1971 to 2006, is available upon request

HPA Centre for Infections

Contact: Geraldine Leong

Tel: +44 (0)20 8200 6868

Email: [geraldine.leong@hpa.org.uk](mailto:geraldine.leong@hpa.org.uk)

Web: [www.hpa.org.uk/infections/topics\\_az/hiv\\_and\\_sti/Stats/STIs/Annual/default.htm](http://www.hpa.org.uk/infections/topics_az/hiv_and_sti/Stats/STIs/Annual/default.htm)

### **Scotland**

Data on selected diagnoses, 1956 to 2006, is available upon request

ISD Scotland

Contact: Kenny McIntyre

Tel: +44(0)131 275 6557;

Email: [kenny.mcintyre@isd.csa.scot.nhs.uk](mailto:kenny.mcintyre@isd.csa.scot.nhs.uk)

Web: [www.isdscotland.org.uk](http://www.isdscotland.org.uk)

### **Wales**

Data on selected diagnoses is available upon request.

Communicable Disease Surveillance Centre Northern Ireland

Contact: Daniel Thomas

Tel: +44(0)29 2040 2471

email: [daniel.thomas@nphs.wales.nhs.uk](mailto:daniel.thomas@nphs.wales.nhs.uk)

Web: [www.hpa.org.uk/infections/topics\\_az/hiv\\_and\\_sti/Stats/STIs/Annual/default.htm](http://www.hpa.org.uk/infections/topics_az/hiv_and_sti/Stats/STIs/Annual/default.htm)

### **Northern Ireland**

Data on selected diagnoses is available upon request.

Communicable Disease Surveillance Centre Northern Ireland

Contact: Brian Smyth

Tel: +44(0)2890 263 765

email: [dbrian.smyth@hpa.org.uk](mailto:dbrian.smyth@hpa.org.uk)

Web: [www.hpa.org.uk/infections/topics\\_az/hiv\\_and\\_sti/Stats/STIs/Annual/default.htm](http://www.hpa.org.uk/infections/topics_az/hiv_and_sti/Stats/STIs/Annual/default.htm)



United Kingdom:

Number of new episodes seen at genitourinary medicine clinics by sex, 1997 - 2006

KC60 codes and conditions			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
A1,A2	Primary and secondary infectious syphilis	Male (all)	107	90	166	264	642	1,119	1,461	1,999	2,384	2,424
		-of which MSM	19	23	53	130	365	653	826	1,074	1,438	1,417
		Female	55	49	57	78	111	139	191	283	420	342
		<b>Total</b>	<b>162</b>	<b>139</b>	<b>223</b>	<b>342</b>	<b>753</b>	<b>1,258</b>	<b>1,652</b>	<b>2,282</b>	<b>2,804</b>	<b>2,766</b>
A3	Early latent syphilis (first 2 years)	Male (all)	82	91	127	134	275	363	459	571	711	745
		-of which MSM	23	20	31	51	118	194	211	301	424	456
		Female	57	58	79	93	104	129	156	201	189	191
		<b>Total</b>	<b>139</b>	<b>149</b>	<b>206</b>	<b>227</b>	<b>379</b>	<b>492</b>	<b>615</b>	<b>772</b>	<b>900</b>	<b>936</b>
A4,A5,A6	Other acquired syphilis	Male (all)	625	654	697	807	882	910	1,051	1,157	1,154	1,142
		-of which MSM	89	79	97	96	128	140	166	171	208	235
		Female	309	381	421	476	652	777	830	897	871	786
		<b>Total</b>	<b>934</b>	<b>1,035</b>	<b>1,118</b>	<b>1,283</b>	<b>1,534</b>	<b>1,687</b>	<b>1,881</b>	<b>2,054</b>	<b>2,025</b>	<b>1,928</b>
A7	Congenital syphilis, aged under 2	Male (all)	1	0	1	6	2	2	3	5	6	2
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	1	2	1	4	0	5	0	3	8	3
		<b>Total</b>	<b>2</b>	<b>2</b>	<b>2</b>	<b>10</b>	<b>2</b>	<b>7</b>	<b>3</b>	<b>8</b>	<b>14</b>	<b>5</b>
A8	Congenital syphilis, aged 2 or over	Male (all)	10	6	7	9	4	7	1	6	9	4
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	14	11	14	4	6	9	5	6	14	6
		<b>Total</b>	<b>24</b>	<b>17</b>	<b>21</b>	<b>13</b>	<b>10</b>	<b>16</b>	<b>6</b>	<b>12</b>	<b>23</b>	<b>10</b>
A9	Epidemiological treatment of suspected syphilis	Male (all)	50	20	31	27	64	168	270	423	535	681
		-of which MSM	7	0	7	6	25	86	161	255	324	435
		Female	53	36	35	26	30	52	70	95	126	129
		<b>Total</b>	<b>103</b>	<b>56</b>	<b>66</b>	<b>53</b>	<b>94</b>	<b>220</b>	<b>340</b>	<b>518</b>	<b>661</b>	<b>810</b>
B1,B2	Uncomplicated gonorrhoea	Male (all)	8,933	8,930	11,326	15,234	16,626	17,871	17,403	15,674	13,876	13,627
		-of which MSM	1,954	1,799	1,966	3,149	3,741	3,618	4,077	3,994	4,386	4,524
		Female	4,130	4,282	5,144	6,566	7,079	7,728	7,562	6,647	5,372	5,380
		<b>Total</b>	<b>13,063</b>	<b>13,212</b>	<b>16,470</b>	<b>21,800</b>	<b>23,705</b>	<b>25,599</b>	<b>24,965</b>	<b>22,321</b>	<b>19,248</b>	<b>19,007</b>
B3	Gonococcal ophthalmia neonatorum	Male (all)	2	3	6	7	7	8	10	10	12	16
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	7	5	7	6	10	13	16	15	81	9
		<b>Total</b>	<b>9</b>	<b>8</b>	<b>13</b>	<b>13</b>	<b>17</b>	<b>21</b>	<b>26</b>	<b>25</b>	<b>93</b>	<b>25</b>
B4	Epidemiological treatment of suspected gonorrhoea	Male (all)	1,417	1,497	1,641	2,282	2,772	3,173	3,512	3,713	3,850	4,068
		-of which MSM	490	462	454	648	868	930	1,165	1,192	1,367	1,473
		Female	1,568	1,586	1,907	2,319	2,705	3,114	3,301	3,268	3,314	3,237
		<b>Total</b>	<b>2,985</b>	<b>3,083</b>	<b>3,548</b>	<b>4,601</b>	<b>5,477</b>	<b>6,287</b>	<b>6,813</b>	<b>6,981</b>	<b>7,164</b>	<b>7,305</b>
B5	Gonococcal complications	Male (all)	72	80	81	85	101	113	110	138	106	97
		-of which MSM	13	12	13	9	14	26	13	19	31	20
		Female	196	192	247	278	287	283	327	277	234	244
		<b>Total</b>	<b>268</b>	<b>272</b>	<b>328</b>	<b>363</b>	<b>388</b>	<b>396</b>	<b>437</b>	<b>415</b>	<b>340</b>	<b>341</b>

UK: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
C1,C2,C3	Chancroid/LGV/Donovanosis	Male (all)	35	46	34	32	30	38	65	88	262	195
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	20	27	24	33	36	39	83	85	67	76
		<b>Total</b>	<b>55</b>	<b>73</b>	<b>58</b>	<b>65</b>	<b>66</b>	<b>77</b>	<b>148</b>	<b>173</b>	<b>329</b>	<b>271</b>
C4A,C4C	Uncomplicated chlamydial infection	Male (all)	17,910	21,064	24,435	29,818	33,362	38,674	43,186	48,626	51,911	56,008
		-of which MSM	387	504	690	1,082	1,531	1,644	2,113	2,228	2,712	3,239
		Female	24,758	27,662	32,556	38,514	43,153	48,918	52,965	56,107	57,507	57,577
		<b>Total</b>	<b>42,668</b>	<b>48,726</b>	<b>56,991</b>	<b>68,332</b>	<b>76,515</b>	<b>87,592</b>	<b>96,151</b>	<b>104,733</b>	<b>109,418</b>	<b>113,585</b>
C4B	Complicated chlamydial infection	Male (all)	365	368	480	569	610	632	700	724	810	808
		-of which MSM	51	31	26	25	40	35	54	49	74	65
		Female	1,449	1,680	1,959	2,365	2,411	2,463	2,424	2,620	2,532	2,505
		<b>Total</b>	<b>1,814</b>	<b>2,048</b>	<b>2,439</b>	<b>2,934</b>	<b>3,021</b>	<b>3,095</b>	<b>3,124</b>	<b>3,344</b>	<b>3,342</b>	<b>3,313</b>
C4D	Chlamydial ophthalmia neonatorum	Male (all)	18	15	18	20	15	18	23	49	22	17
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	17	17	13	29	29	26	26	41	23	22
		<b>Total</b>	<b>35</b>	<b>32</b>	<b>31</b>	<b>49</b>	<b>44</b>	<b>44</b>	<b>49</b>	<b>90</b>	<b>45</b>	<b>39</b>
C4E	Epidemiological treatment of suspected chlamydial infection	Male (all)	8,818	10,305	12,823	15,700	19,471	23,946	25,166	27,418	29,305	28,992
		-of which MSM	219	213	277	479	726	1,147	1,492	1,613	1,913	2,151
		Female	6,741	7,732	9,221	11,202	13,291	15,678	16,316	18,682	20,709	21,002
		<b>Total</b>	<b>15,559</b>	<b>18,037</b>	<b>22,044</b>	<b>26,902</b>	<b>32,762</b>	<b>39,624</b>	<b>41,482</b>	<b>46,100</b>	<b>50,014</b>	<b>49,994</b>
C4H*	Uncomplicated non-gonococcal/non-spec urethritis males(females) treatment of mucopurulent cervicitis	Male (all)	52,687	56,180	57,963	60,933	64,414	67,286	72,573	75,892	76,254	76,108
		-of which MSM	3,166	3,487	3,603	4,089	4,839	4,838	5,287	5,441	5,547	5,983
		Female	181	176	197	160	129	134	7,038	7,875	7,981	7,402
		<b>Total</b>	<b>52,868</b>	<b>56,356</b>	<b>58,160</b>	<b>61,093</b>	<b>64,543</b>	<b>67,420</b>	<b>79,611</b>	<b>83,767</b>	<b>84,235</b>	<b>83,510</b>
C4I	Epidemiological treatment of NSGI	Male (all)	5,297	5,496	6,413	6,497	6,363	6,294	6,436	6,592	6,130	6,088
		-of which MSM	506	461	733	646	723	670	800	829	775	850
		Female	17,976	19,361	19,880	20,410	21,161	20,137	18,239	18,611	18,323	17,598
		<b>Total</b>	<b>23,273</b>	<b>24,857</b>	<b>26,293</b>	<b>26,907</b>	<b>27,524</b>	<b>26,431</b>	<b>24,675</b>	<b>25,203</b>	<b>24,453</b>	<b>23,686</b>
C5	Complicated infection non-gonococcal/non-chlamydial	Male (all)	2,816	2,717	3,341	3,865	4,045	4,217	4,279	4,674	5,427	5,140
		-of which MSM	189	159	221	216	248	239	257	286	368	356
		Female	9,454	10,295	10,790	11,431	11,534	11,968	11,382	13,233	12,721	13,138
		<b>Total</b>	<b>12,270</b>	<b>13,012</b>	<b>14,131</b>	<b>15,296</b>	<b>15,579</b>	<b>16,185</b>	<b>15,661</b>	<b>17,907</b>	<b>18,148</b>	<b>18,278</b>
C6A	Trichomoniasis	Male (all)	278	319	670	747	775	614	318	347	387	374
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	5,910	6,119	5,640	6,196	6,479	6,804	6,390	6,093	5,241	5,409
		<b>Total</b>	<b>6,188</b>	<b>6,438</b>	<b>6,310</b>	<b>6,943</b>	<b>7,254</b>	<b>7,418</b>	<b>6,708</b>	<b>6,440</b>	<b>5,628</b>	<b>5,783</b>
C6B	Anaerobic/bacterial vaginosis & anaerobic balanitis	Male (all)	1,502	1,530	1,512	1,455	1,531	1,488	1,533	1,534	1,603	1,814
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	50,084	54,973	59,202	64,807	69,403	76,154	77,403	75,403	77,525	80,225
		<b>Total</b>	<b>51,586</b>	<b>56,503</b>	<b>60,714</b>	<b>66,262</b>	<b>70,934</b>	<b>77,642</b>	<b>78,936</b>	<b>76,937</b>	<b>79,128</b>	<b>82,039</b>
C6C	Other vaginosis/vaginitis/balanitis	Male (all)	13,315	13,852	13,632	13,605	13,745	13,486	13,629	13,576	13,042	13,010
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	7,801	8,892	7,817	7,314	7,062	5,895	5,655	6,061	5,105	5,255
		<b>Total</b>	<b>21,116</b>	<b>22,744</b>	<b>21,449</b>	<b>20,919</b>	<b>20,807</b>	<b>19,381</b>	<b>19,284</b>	<b>19,637</b>	<b>18,147</b>	<b>18,265</b>

UK: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	
C7A	Genital candidosis	Male (all)	9,003	8,790	8,334	8,055	8,359	7,880	6,949	6,777	6,606	7,421	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	68,608	67,508	68,546	70,202	74,608	75,268	71,368	67,921	64,831	64,107	64,107
	<b>Total</b>	<b>77,611</b>	<b>76,298</b>	<b>76,880</b>	<b>78,257</b>	<b>82,967</b>	<b>83,148</b>	<b>78,317</b>	<b>74,698</b>	<b>71,437</b>	<b>71,528</b>	<b>71,528</b>	
C7B	Epidemiological treatment of C6 & C7	Male (all)	4,049	3,694	3,688	3,386	3,761	4,275	4,332	4,284	4,438	4,329	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	6,913	6,289	6,468	5,807	6,704	6,741	7,133	8,004	7,386	7,391	7,391
	<b>Total</b>	<b>10,962</b>	<b>9,983</b>	<b>10,156</b>	<b>9,193</b>	<b>10,465</b>	<b>11,016</b>	<b>11,465</b>	<b>12,288</b>	<b>11,824</b>	<b>11,720</b>	<b>11,720</b>	
C8,C9	Scabies/pediculosis pubis	Male (all)	5,178	5,132	5,044	5,225	4,687	4,091	3,524	2,799	2,230	2,239	
		-of which MSM	900	861	830	951	931	834	723	600	556	601	
		Female	1,666	1,654	1,452	1,296	1,062	825	593	456	341	313	
	<b>Total</b>	<b>6,844</b>	<b>6,786</b>	<b>6,496</b>	<b>6,521</b>	<b>5,749</b>	<b>4,916</b>	<b>4,117</b>	<b>3,255</b>	<b>2,571</b>	<b>2,552</b>	<b>2,552</b>	
C10A	Genital herpes simplex – first attack	Male (all)	6,208	6,688	6,660	6,812	7,200	7,215	7,208	7,236	7,596	8,392	
		-of which MSM	355	329	372	439	447	525	523	525	626	604	
		Female	10,407	10,560	10,849	11,011	11,744	12,211	12,023	11,837	12,234	13,306	
	<b>Total</b>	<b>16,615</b>	<b>17,248</b>	<b>17,509</b>	<b>17,823</b>	<b>18,944</b>	<b>19,426</b>	<b>19,231</b>	<b>19,073</b>	<b>19,830</b>	<b>21,698</b>	<b>21,698</b>	
C10B	Genital herpes simplex – recurrence	Male (all)	6,028	5,987	6,428	6,590	6,770	6,964	6,938	6,717	6,917	7,256	
		-of which MSM	418	382	422	463	438	440	503	510	568	573	
		Female	7,166	7,277	7,741	7,891	8,691	8,822	8,701	8,427	8,718	9,098	
	<b>Total</b>	<b>13,194</b>	<b>13,264</b>	<b>14,169</b>	<b>14,481</b>	<b>15,461</b>	<b>15,786</b>	<b>15,639</b>	<b>15,144</b>	<b>15,635</b>	<b>16,354</b>	<b>16,354</b>	
C11A	Genital warts – first attack	Male (all)	35,521	36,522	37,482	37,633	38,522	39,899	40,590	42,725	42,979	44,445	
		-of which MSM	1,639	1,672	1,760	1,877	1,987	2,231	2,397	2,396	2,593	2,691	
		Female	33,362	33,769	34,266	33,684	34,936	35,092	36,008	37,330	38,222	39,300	
	<b>Total</b>	<b>68,883</b>	<b>70,291</b>	<b>71,748</b>	<b>71,317</b>	<b>73,458</b>	<b>74,991</b>	<b>76,598</b>	<b>80,055</b>	<b>81,201</b>	<b>83,745</b>	<b>83,745</b>	
C11B	Genital warts – recurrence	Male (all)	23,726	25,462	25,385	25,420	25,620	24,973	24,690	25,185	26,433	27,772	
		-of which MSM	1,314	1,330	1,325	1,337	1,484	1,513	1,693	1,801	1,741	1,894	
		Female	13,493	13,994	13,861	14,051	13,869	13,748	14,179	14,619	15,631	16,883	
	<b>Total</b>	<b>37,219</b>	<b>39,456</b>	<b>39,246</b>	<b>39,471</b>	<b>39,489</b>	<b>38,721</b>	<b>38,869</b>	<b>39,804</b>	<b>42,064</b>	<b>44,655</b>	<b>44,655</b>	
C11C	Genital warts – re-registered cases†	Male (all)	8,568	10,113	10,435	9,992	9,864	9,269	9,551	9,261	9,526	10,115	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	7,476	8,386	8,535	8,036	7,869	7,099	7,200	7,126	7,447	7,706	
	<b>Total</b>	<b>16,044</b>	<b>18,499</b>	<b>18,970</b>	<b>18,028</b>	<b>17,733</b>	<b>16,368</b>	<b>16,751</b>	<b>16,387</b>	<b>16,973</b>	<b>17,821</b>	<b>17,821</b>	
C12	Molluscum contagiosum	Male (all)	4,312	4,711	5,186	5,594	6,049	6,704	7,546	8,728	9,698	10,566	
		-of which MSM	298	228	238	221	243	231	273	285	325	336	
		Female	2,415	2,616	2,897	2,955	3,277	3,515	3,810	4,276	4,684	4,957	
	<b>Total</b>	<b>6,727</b>	<b>7,327</b>	<b>8,083</b>	<b>8,549</b>	<b>9,326</b>	<b>10,219</b>	<b>11,356</b>	<b>13,004</b>	<b>14,382</b>	<b>15,523</b>	<b>15,523</b>	
C13	Antigen positive viral hepatitis B	Male (all)	666	589	565	669	748	962	23	31	17	25	
		-of which MSM	148	112	109	135	165	203	9	15	6	3	
		Female	193	211	264	238	364	496	6	7	3	7	
	<b>Total</b>	<b>859</b>	<b>800</b>	<b>829</b>	<b>907</b>	<b>1,112</b>	<b>1,458</b>	<b>29</b>	<b>38</b>	<b>20</b>	<b>32</b>	<b>32</b>	
C13A*	Viral hepatitis B (HbsAg positive): first diagnosis**	Male (all)	-	-	-	-	-	-	618	672	655	655	
		-of which MSM	-	-	-	-	-	-	114	93	91	54	
		Female	-	-	-	-	-	-	276	328	329	334	
	<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>894</b>	<b>1,000</b>	<b>984</b>	<b>989</b>	<b>989</b>	

UK: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	
C13B*	**number of which were acute viral hepatitis B	Male (all)	-	-	-	-	-	-	47	55	48	39	
		-of which MSM	-	-	-	-	-	-	14	19	14	7	
		Female	-	-	-	-	-	-	11	12	30	26	
		<b>Total</b>	-	-	-	-	-	-	<b>58</b>	<b>67</b>	<b>78</b>	<b>65</b>	
C13C*	Viral hepatitis B: subsequent presentation	Male (all)	-	-	-	-	-	-	347	462	419	433	
		-of which MSM	-	-	-	-	-	-	121	205	207	228	
		Female	-	-	-	-	-	-	151	169	165	205	
		<b>Total</b>	-	-	-	-	-	-	<b>498</b>	<b>631</b>	<b>584</b>	<b>638</b>	
C14*	Viral hepatitis C: fist diagnosis (previous to 2003 C14 was other viral hepatitis)	Male (all)	1,119	1,069	957	980	955	1,096	1,054	1,116	1,029	957	
		-of which MSM	142	132	83	106	105	145	110	126	123	121	
		Female	431	456	454	445	396	501	488	472	447	386	
		<b>Total</b>	<b>1,550</b>	<b>1,525</b>	<b>1,411</b>	<b>1,425</b>	<b>1,351</b>	<b>1,597</b>	<b>1,542</b>	<b>1,588</b>	<b>1,476</b>	<b>1,343</b>	
E1A	New HIV diagnosis - asymptomatic	Male (all)	1,194	1,166	1,125	1,244	1,713	2,364	2,737	2,922	3,154	2,956	
		-of which MSM	651	585	551	624	770	772	1,134	1,299	1,501	1,400	
		Female	373	374	589	691	1,137	2,012	2,154	2,116	2,110	1,863	
		<b>Total</b>	<b>1,567</b>	<b>1,540</b>	<b>1,714</b>	<b>1,935</b>	<b>2,850</b>	<b>4,376</b>	<b>4,891</b>	<b>5,038</b>	<b>5,264</b>	<b>4,819</b>	
E1B*	Asymptomatic HIV infection – subsequent presentation	Male (all)	6,591	7,000	7,502	8,173	8,758	10,395	202	629	832	915	
		-of which MSM	423	490	557	122	76	47	84	426	656	691	
		Female	1,661	1,964	2,280	3,006	3,872	5,634	56	222	202	307	
		<b>Total</b>	<b>8,252</b>	<b>8,964</b>	<b>9,782</b>	<b>11,179</b>	<b>12,630</b>	<b>16,029</b>	<b>258</b>	<b>851</b>	<b>1,034</b>	<b>1,222</b>	
E1BE2B*	Subsequent HIV presentation (not AIDS)	Male (all)	-	-	-	-	-	-	26,089	31,372	38,437	40,021	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	-	-	-	-	-	-	-	12,317	16,561	20,823	21,966
		<b>Total</b>	-	-	-	-	-	-	-	<b>38,406</b>	<b>47,933</b>	<b>59,260</b>	<b>61,987</b>
E2A	New HIV diagnosis: symptomatic (not AIDS)	Male (all)	956	612	548	513	684	772	694	701	767	673	
		-of which MSM	563	320	294	244	330	265	278	263	276	256	
		Female	237	202	198	210	335	457	459	402	453	362	
		<b>Total</b>	<b>1,193</b>	<b>814</b>	<b>746</b>	<b>723</b>	<b>1,019</b>	<b>1,229</b>	<b>1,153</b>	<b>1,103</b>	<b>1,220</b>	<b>1,035</b>	
E2B*	HIV infection with symptoms, not AIDS – subsequent presentation	Male (all)	7,491	8,590	8,689	9,421	9,508	9,607	63	433	502	467	
		-of which MSM	565	508	521	104	7	8	38	328	405	357	
		Female	1,381	1,902	2,065	2,376	2,699	3,387	8	107	79	76	
		<b>Total</b>	<b>8,872</b>	<b>10,492</b>	<b>10,754</b>	<b>11,797</b>	<b>12,207</b>	<b>12,994</b>	<b>71</b>	<b>540</b>	<b>581</b>	<b>543</b>	
E3A*	AIDS – first presentation	Male (all)	697	448	414	383	448	470	3	4	5	7	
		-of which MSM	367	196	167	189	175	177	0	3	1	4	
		Female	162	135	112	141	217	237	0	2	0	2	
		<b>Total</b>	<b>859</b>	<b>583</b>	<b>526</b>	<b>524</b>	<b>665</b>	<b>707</b>	<b>3</b>	<b>6</b>	<b>5</b>	<b>9</b>	
E3A1*	AIDS: first presentation - new HIV diagnosis	Male (all)	-	-	-	-	-	-	182	222	231	192	
		-of which MSM	-	-	-	-	-	-	73	62	77	63	
		Female	-	-	-	-	-	-	143	120	150	91	
		<b>Total</b>	-	-	-	-	-	-	<b>325</b>	<b>342</b>	<b>381</b>	<b>283</b>	
E3A2*	AIDS: first presentation - HIV diagnosed previously	Male (all)	-	-	-	-	-	-	240	156	162	161	
		-of which MSM	-	-	-	-	-	-	97	76	61	84	
		Female	-	-	-	-	-	-	135	65	70	74	
		<b>Total</b>	-	-	-	-	-	-	<b>375</b>	<b>221</b>	<b>232</b>	<b>235</b>	

UK: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
E3B	AIDS – subsequent presentation	Male (all)	5,024	5,809	6,060	6,625	7,046	7,965	9,761	10,582	11,986	12,006
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	844	1,201	1,381	1,683	2,125	2,666	4,059	4,418	5,042	5,234
	<b>Total</b>	<b>5,868</b>	<b>7,010</b>	<b>7,441</b>	<b>8,308</b>	<b>9,171</b>	<b>10,631</b>	<b>13,820</b>	<b>15,000</b>	<b>17,028</b>	<b>17,240</b>	
D2A	Urinary tract infection	Male (all)	1,927	2,040	2,138	2,010	2,101	2,623	2,627	2,588	2,134	2,248
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	8,972	8,955	9,349	9,642	9,743	9,476	9,041	10,118	9,691	10,213
	<b>Total</b>	<b>10,899</b>	<b>10,995</b>	<b>11,487</b>	<b>11,652</b>	<b>11,844</b>	<b>12,099</b>	<b>11,668</b>	<b>12,706</b>	<b>11,825</b>	<b>12,461</b>	
D2B	Other conditions requiring treatment at GUM clinic	Male (all)	50,343	55,630	56,498	58,716	58,976	62,348	69,195	70,162	72,987	75,462
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	51,533	51,692	51,699	56,342	57,158	58,181	56,782	57,895	58,977	60,866
	<b>Total</b>	<b>101,876</b>	<b>107,322</b>	<b>108,197</b>	<b>115,058</b>	<b>116,134</b>	<b>120,529</b>	<b>125,977</b>	<b>128,057</b>	<b>131,964</b>	<b>136,328</b>	
D3**	Other episodes	Male (all)	99,089	108,395	112,394	118,230	139,176	158,698	151,042	181,913	204,825	225,008
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	107,959	116,237	120,252	123,430	143,377	161,257	150,509	176,625	203,982	221,487
	<b>Total</b>	<b>207,048</b>	<b>224,632</b>	<b>232,646</b>	<b>241,660</b>	<b>282,553</b>	<b>319,955</b>	<b>301,551</b>	<b>358,538</b>	<b>408,807</b>	<b>446,495</b>	
P1A	HIV antibody test (no sexual health screen)	Male (all)	72,722	77,413	79,819	90,280	117,896	156,968	58,634	57,271	42,381	36,579
		-of which MSM	11,028	11,887	12,041	13,340	17,432	20,183	10,010	9,695	8,271	7,732
		Female	57,679	61,758	63,346	71,831	98,559	138,333	44,688	41,446	31,737	27,319
	<b>Total</b>	<b>130,401</b>	<b>139,171</b>	<b>143,165</b>	<b>162,111</b>	<b>216,455</b>	<b>295,301</b>	<b>103,322</b>	<b>98,717</b>	<b>74,118</b>	<b>63,898</b>	
P1B	HIV antibody test offered and refused	Male (all)	12,319	13,484	13,825	15,220	20,396	45,408	100,366	127,092	127,295	123,716
		-of which MSM	995	1,167	1,492	1,234	1,765	3,335	6,188	6,973	7,194	7,174
		Female	11,932	12,481	13,086	14,236	20,035	50,307	114,581	143,218	145,051	142,889
	<b>Total</b>	<b>24,251</b>	<b>25,965</b>	<b>26,911</b>	<b>29,456</b>	<b>40,431</b>	<b>95,715</b>	<b>214,947</b>	<b>270,310</b>	<b>272,346</b>	<b>266,605</b>	
P2	Hepatitis B vaccination (1st dose only)	Male (all)	9,530	10,233	10,324	11,277	12,427	14,001	14,968	16,659	16,506	17,070
		-of which MSM	4,758	4,967	4,892	5,387	6,114	6,961	8,095	8,779	8,969	8,935
		Female	2,352	2,671	2,574	2,718	3,243	4,009	4,223	5,252	5,637	6,063
	<b>Total</b>	<b>11,882</b>	<b>12,904</b>	<b>12,898</b>	<b>13,995</b>	<b>15,670</b>	<b>18,010</b>	<b>19,191</b>	<b>21,911</b>	<b>22,143</b>	<b>23,133</b>	
P3	Contraception (excluding condom provision)	Male (all)	-	-	-	-	-	-	-	-	-	-
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	26,167	32,182	30,705	33,389	34,075	31,920	33,102	34,664	35,861	39,670
	<b>Total</b>	<b>26,167</b>	<b>32,182</b>	<b>30,705</b>	<b>33,389</b>	<b>34,075</b>	<b>31,920</b>	<b>33,102</b>	<b>34,676</b>	<b>35,943</b>	<b>39,826</b>	
P4A	Cervical cytology - minor abnormality	Male (all)	-	-	-	-	-	-	-	-	-	-
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	11,107	10,036	8,060	6,509	4,926	3,848	5,355	3,450	1,771	1,519
	<b>Total</b>	<b>11,107</b>	<b>10,036</b>	<b>8,060</b>	<b>6,509</b>	<b>4,926</b>	<b>3,848</b>	<b>5,355</b>	<b>3,450</b>	<b>1,771</b>	<b>1,519</b>	
P4B	Cervical cytology - major abnormality	Male (all)	-	-	-	-	-	-	-	-	-	-
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	1,711	1,412	1,231	1,146	1,033	765	923	813	398	300
	<b>Total</b>	<b>1,711</b>	<b>1,412</b>	<b>1,231</b>	<b>1,146</b>	<b>1,033</b>	<b>765</b>	<b>923</b>	<b>813</b>	<b>398</b>	<b>300</b>	

UK: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
S1*	Sexual health screen (no HIV antibody test)	Male (all)	-	-	-	-	-	-	151,358	153,379	147,782	144,163
		-of which MSM	-	-	-	-	-	-	9,950	10,083	11,329	12,524
		Female	-	-	-	-	-	-	185,561	184,759	180,119	175,101
		<b>Total</b>	-	-	-	-	-	-	<b>336,919</b>	<b>338,138</b>	<b>327,901</b>	<b>319,264</b>
S2*	HIV antibody test and sexual health screen	Male (all)	-	-	-	-	-	-	163,124	214,139	281,824	326,832
		-of which MSM	-	-	-	-	-	-	16,309	19,549	25,980	30,715
		Female	-	-	-	-	-	-	159,709	207,431	272,868	314,772
		<b>Total</b>	-	-	-	-	-	-	<b>322,833</b>	<b>421,570</b>	<b>554,692</b>	<b>641,604</b>
<b>Total new STI diagnoses</b>		Male (all)	136,572	144,625	154,541	168,567	179,460	191,608	202,575	213,495	218,072	224,244
		-of which MSM	10,185	10,010	10,617	13,056	15,486	15,911	18,028	18,521	20,511	21,558
		Female	94,613	99,657	106,865	115,468	123,709	132,588	143,551	149,753	150,269	152,264
		<b>Total</b>	<b>231,185</b>	<b>244,282</b>	<b>261,406</b>	<b>284,035</b>	<b>303,169</b>	<b>324,196</b>	<b>346,126</b>	<b>363,248</b>	<b>368,341</b>	<b>376,508</b>
<b>Total other STI diagnoses</b>		Male (all)	74,445	81,496	86,677	92,093	97,869	104,532	114,468	124,283	136,534	140,475
		-of which MSM	4,693	4,447	4,933	4,268	4,810	5,392	6,451	7,605	8,586	9,423
		Female	58,926	64,048	67,553	71,753	77,330	81,533	85,614	93,366	101,670	104,329
		<b>Total</b>	<b>133,371</b>	<b>145,544</b>	<b>154,230</b>	<b>163,846</b>	<b>175,199</b>	<b>186,065</b>	<b>200,082</b>	<b>217,649</b>	<b>238,204</b>	<b>244,804</b>
<b>Total other GUM clinic diagnoses</b>		Male (all)	81,924	87,194	87,324	88,877	90,176	94,159	100,355	99,695	100,639	103,921
		-of which MSM	1,157	1,353	1,292	1,094	1,032	1,448	1,700	1,051	913	908
		Female	207,353	210,424	213,090	222,452	231,398	237,325	234,593	230,435	226,271	230,393
		<b>Total</b>	<b>289,277</b>	<b>297,618</b>	<b>300,414</b>	<b>311,329</b>	<b>321,574</b>	<b>331,484</b>	<b>334,948</b>	<b>330,130</b>	<b>326,910</b>	<b>334,314</b>
<b>Total services provided</b>		Male (all)	193,660	209,525	216,362	235,007	289,895	375,075	639,492	752,027	823,034	875,996
		-of which MSM	17,483	18,914	19,538	20,835	26,354	31,878	52,108	58,479	66,686	72,186
		Female	206,089	225,329	229,963	245,604	299,289	385,826	692,373	793,617	875,642	927,743
		<b>Total</b>	<b>399,749</b>	<b>434,854</b>	<b>446,325</b>	<b>480,611</b>	<b>589,184</b>	<b>760,901</b>	<b>1,331,865</b>	<b>1,545,644</b>	<b>1,698,676</b>	<b>1,803,739</b>

Source: HPA Centre for Infections

\* KC60 codes were created/revised in quarter 3, 2002

\*\* All Scottish 'V' codes are mapped to English code D3, excluding V1B which maps to English code P2

† previous diagnosis of C11a or C11b treated for more than 3 months

- data not available/applicable



England:

Number of new episodes seen at genitourinary medicine clinics by sex, 1997 - 2006

KC60 codes and conditions			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
A1,A2	Primary and secondary infectious syphilis	Male (all)	98	87	156	247	618	1,059	1,355	1,767	2,168	2,185
		-of which MSM	18	23	52	119	351	613	759	903	1,269	1,225
		Female	49	44	55	75	99	137	183	266	406	330
		<b>Total</b>	<b>147</b>	<b>131</b>	<b>211</b>	<b>322</b>	<b>717</b>	<b>1,196</b>	<b>1,538</b>	<b>2,033</b>	<b>2,574</b>	<b>2,515</b>
A3	Early latent syphilis (first 2 years)	Male (all)	77	87	122	126	268	330	425	526	660	672
		-of which MSM	21	18	30	48	114	177	194	271	384	407
		Female	55	58	75	93	99	121	150	197	175	173
		<b>Total</b>	<b>132</b>	<b>145</b>	<b>197</b>	<b>219</b>	<b>367</b>	<b>451</b>	<b>575</b>	<b>723</b>	<b>835</b>	<b>845</b>
A4,A5,A6	Other acquired syphilis	Male (all)	596	625	671	778	847	866	1,017	1,111	1,076	1,082
		-of which MSM	84	75	93	87	122	130	157	157	178	217
		Female	300	370	405	470	638	746	805	864	835	751
		<b>Total</b>	<b>896</b>	<b>995</b>	<b>1,076</b>	<b>1,248</b>	<b>1,485</b>	<b>1,612</b>	<b>1,822</b>	<b>1,975</b>	<b>1,911</b>	<b>1,833</b>
A7	Congenital syphilis, aged under 2	Male (all)	1	0	1	5	2	2	3	4	6	2
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	0	2	1	4	0	5	0	3	8	3
		<b>Total</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>9</b>	<b>2</b>	<b>7</b>	<b>3</b>	<b>7</b>	<b>14</b>	<b>5</b>
A8	Congenital syphilis, aged 2 or over	Male (all)	10	6	5	9	3	5	1	5	9	4
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	13	10	12	4	6	9	4	4	13	5
		<b>Total</b>	<b>23</b>	<b>16</b>	<b>17</b>	<b>13</b>	<b>9</b>	<b>14</b>	<b>5</b>	<b>9</b>	<b>22</b>	<b>9</b>
A9	Epidemiological treatment of suspected syphilis	Male (all)	50	19	24	26	61	157	255	366	486	640
		-of which MSM	7	0	7	6	23	81	148	210	283	399
		Female	53	36	34	26	30	49	66	89	122	122
		<b>Total</b>	<b>103</b>	<b>55</b>	<b>58</b>	<b>52</b>	<b>91</b>	<b>206</b>	<b>321</b>	<b>455</b>	<b>608</b>	<b>762</b>
B1,B2	Uncomplicated gonorrhoea	Male (all)	8,418	8,446	10,669	14,272	15,654	16,940	16,268	14,514	12,683	12,407
		-of which MSM	1,779	1,677	1,812	2,867	3,454	3,298	3,653	3,619	3,922	4,045
		Female	3,981	4,089	4,880	6,222	6,744	7,417	7,224	6,265	5,019	5,038
		<b>Total</b>	<b>12,399</b>	<b>12,535</b>	<b>15,549</b>	<b>20,494</b>	<b>22,398</b>	<b>24,357</b>	<b>23,492</b>	<b>20,779</b>	<b>17,702</b>	<b>17,445</b>
B3	Gonococcal ophthalmia neonatorum	Male (all)	2	3	5	7	7	8	7	10	9	15
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	6	5	7	6	9	9	15	14	81	8
		<b>Total</b>	<b>8</b>	<b>8</b>	<b>12</b>	<b>13</b>	<b>16</b>	<b>17</b>	<b>22</b>	<b>24</b>	<b>90</b>	<b>23</b>
B4	Epidemiological treatment of suspected gonorrhoea	Male (all)	1,348	1,421	1,557	2,112	2,588	3,012	3,301	3,449	3,516	3,742
		-of which MSM	458	441	429	597	815	879	1,080	1,103	1,235	1,330
		Female	1,494	1,519	1,789	2,189	2,563	2,944	3,134	3,064	3,075	2,952
		<b>Total</b>	<b>2,842</b>	<b>2,940</b>	<b>3,346</b>	<b>4,301</b>	<b>5,151</b>	<b>5,956</b>	<b>6,435</b>	<b>6,513</b>	<b>6,591</b>	<b>6,694</b>
B5	Gonococcal complications	Male (all)	68	78	74	79	95	106	99	135	104	92
		-of which MSM	13	11	12	8	14	25	10	19	31	17
		Female	192	183	237	260	273	272	315	262	225	232
		<b>Total</b>	<b>260</b>	<b>261</b>	<b>311</b>	<b>339</b>	<b>368</b>	<b>378</b>	<b>414</b>	<b>397</b>	<b>329</b>	<b>324</b>

England: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
C1,C2,C3	Chancroid/LGV/Donovanosis	Male (all)	32	43	28	30	29	34	60	86	258	189
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	18	24	23	31	33	37	76	63	59	63
		<b>Total</b>	<b>50</b>	<b>67</b>	<b>51</b>	<b>61</b>	<b>62</b>	<b>71</b>	<b>136</b>	<b>149</b>	<b>317</b>	<b>252</b>
C4A,C4C	Uncomplicated chlamydial infection	Male (all)	16,180	18,937	21,776	26,579	29,562	34,331	37,996	42,681	45,155	48,863
		-of which MSM	353	454	621	962	1,365	1,422	1,725	1,789	2,260	2,699
		Female	22,659	24,975	29,184	34,791	38,618	43,786	47,520	50,267	50,775	50,367
		<b>Total</b>	<b>38,839</b>	<b>43,912</b>	<b>50,960</b>	<b>61,370</b>	<b>68,180</b>	<b>78,117</b>	<b>85,516</b>	<b>92,948</b>	<b>95,930</b>	<b>99,230</b>
C4B	Complicated chlamydial infection	Male (all)	339	331	432	528	545	571	637	653	723	746
		-of which MSM	51	31	25	23	35	32	52	45	70	64
		Female	1,286	1,521	1,763	2,114	2,074	2,134	2,091	2,311	2,236	2,204
		<b>Total</b>	<b>1,625</b>	<b>1,852</b>	<b>2,195</b>	<b>2,642</b>	<b>2,619</b>	<b>2,705</b>	<b>2,728</b>	<b>2,964</b>	<b>2,959</b>	<b>2,950</b>
C4D	Chlamydial ophthalmia neonatorum	Male (all)	18	15	15	19	15	15	18	42	15	13
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	14	15	12	23	28	25	25	34	22	18
		<b>Total</b>	<b>32</b>	<b>30</b>	<b>27</b>	<b>42</b>	<b>43</b>	<b>40</b>	<b>43</b>	<b>76</b>	<b>37</b>	<b>31</b>
C4E	Epidemiological treatment of suspected chlamydial infection	Male (all)	7,967	9,086	11,291	14,023	17,345	21,502	22,531	24,371	25,987	25,324
		-of which MSM	191	189	243	405	620	1,032	1,282	1,372	1,627	1,860
		Female	6,195	6,907	8,243	10,118	12,096	14,207	14,651	16,668	18,494	18,676
		<b>Total</b>	<b>14,162</b>	<b>15,993</b>	<b>19,534</b>	<b>24,141</b>	<b>29,441</b>	<b>35,709</b>	<b>37,182</b>	<b>41,039</b>	<b>44,481</b>	<b>44,000</b>
C4H*	Uncomplicated non-gonococcal/non-spec urethritis males(females) treatment of mucopurulent cervicitis	Male (all)	48,677	51,951	53,214	56,007	59,467	62,040	67,292	69,870	70,396	70,667
		-of which MSM	3,021	3,339	3,375	3,847	4,566	4,470	5,000	5,051	5,195	5,672
		Female	0	0	0	0	0	0	6,636	7,417	7,381	6,695
		<b>Total</b>	<b>48,677</b>	<b>51,951</b>	<b>53,214</b>	<b>56,007</b>	<b>59,467</b>	<b>62,040</b>	<b>73,928</b>	<b>77,287</b>	<b>77,777</b>	<b>77,362</b>
C4I	Epidemiological treatment of NSGI	Male (all)	4,892	5,168	6,053	6,141	5,907	5,899	5,958	6,213	5,747	5,640
		-of which MSM	494	442	720	608	674	605	734	791	738	808
		Female	16,764	18,133	18,504	18,773	19,558	18,534	16,915	17,097	16,924	16,200
		<b>Total</b>	<b>21,656</b>	<b>23,301</b>	<b>24,557</b>	<b>24,914</b>	<b>25,465</b>	<b>24,433</b>	<b>22,873</b>	<b>23,310</b>	<b>22,671</b>	<b>21,840</b>
C5	Complicated infection non-gonococcal/non-chlamydial	Male (all)	2,523	2,431	3,008	3,498	3,713	3,874	3,956	4,364	5,025	4,762
		-of which MSM	173	153	206	198	237	216	239	275	340	328
		Female	8,989	9,858	10,228	10,799	10,943	11,324	10,752	12,512	11,969	12,400
		<b>Total</b>	<b>11,512</b>	<b>12,289</b>	<b>13,236</b>	<b>14,297</b>	<b>14,656</b>	<b>15,198</b>	<b>14,708</b>	<b>16,876</b>	<b>16,994</b>	<b>17,162</b>
C6A	Trichomoniasis	Male (all)	255	298	641	731	733	568	285	297	330	315
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	5,713	5,877	5,448	6,036	6,279	6,628	6,224	5,924	5,058	5,206
		<b>Total</b>	<b>5,968</b>	<b>6,175</b>	<b>6,089</b>	<b>6,767</b>	<b>7,012</b>	<b>7,196</b>	<b>6,509</b>	<b>6,221</b>	<b>5,388</b>	<b>5,521</b>
C6B	Anaerobic/bacterial vaginosis & anaerobic balanitis	Male (all)	1,387	1,403	1,388	1,314	1,392	1,391	1,444	1,420	1,474	1,642
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	46,711	51,381	55,518	60,667	64,884	70,909	71,917	69,426	70,642	73,647
		<b>Total</b>	<b>48,098</b>	<b>52,784</b>	<b>56,906</b>	<b>61,981</b>	<b>66,276</b>	<b>72,300</b>	<b>73,361</b>	<b>70,846</b>	<b>72,116</b>	<b>75,289</b>
C6C	Other vaginosis/vaginitis/balanitis	Male (all)	11,884	12,324	11,996	12,049	11,972	11,660	11,827	11,644	11,053	11,121
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	7,652	8,713	7,643	7,079	6,753	5,680	5,382	5,816	4,850	5,055
		<b>Total</b>	<b>19,536</b>	<b>21,037</b>	<b>19,639</b>	<b>19,128</b>	<b>18,725</b>	<b>17,340</b>	<b>17,209</b>	<b>17,460</b>	<b>15,903</b>	<b>16,176</b>

England: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	
C7A	Genital candidosis	Male (all)	7,709	7,523	7,219	6,958	7,165	6,828	5,970	5,947	5,591	6,339	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	63,953	63,016	64,196	65,686	69,918	70,401	66,661	62,919	59,340	58,663	
	<b>Total</b>	<b>71,662</b>	<b>70,539</b>	<b>71,415</b>	<b>72,644</b>	<b>77,083</b>	<b>77,229</b>	<b>72,631</b>	<b>68,866</b>	<b>64,931</b>	<b>65,002</b>		
C7B	Epidemiological treatment of C6 & C7	Male (all)	3,958	3,630	3,621	3,351	3,729	4,177	4,263	4,197	4,373	4,270	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	6,831	6,250	6,395	5,773	6,676	6,674	7,062	7,920	7,307	7,336	
	<b>Total</b>	<b>10,789</b>	<b>9,880</b>	<b>10,016</b>	<b>9,124</b>	<b>10,405</b>	<b>10,851</b>	<b>11,325</b>	<b>12,117</b>	<b>11,680</b>	<b>11,606</b>		
C8,C9	Scabies/pediculosis pubis	Male (all)	4,618	4,565	4,491	4,611	4,178	3,592	3,058	2,420	1,884	1,914	
		-of which MSM	806	762	741	826	805	708	597	501	448	480	
		Female	1,489	1,505	1,320	1,150	948	707	504	393	295	274	
	<b>Total</b>	<b>6,107</b>	<b>6,070</b>	<b>5,811</b>	<b>5,761</b>	<b>5,126</b>	<b>4,299</b>	<b>3,562</b>	<b>2,813</b>	<b>2,179</b>	<b>2,188</b>		
C10A	Genital herpes simplex – first attack	Male (all)	5,597	6,140	6,031	6,175	6,489	6,522	6,449	6,438	6,800	7,480	
		-of which MSM	334	301	338	384	399	479	468	458	550	517	
		Female	9,482	9,675	9,849	9,972	10,565	10,988	10,708	10,514	10,818	11,908	
	<b>Total</b>	<b>15,079</b>	<b>15,815</b>	<b>15,880</b>	<b>16,147</b>	<b>17,054</b>	<b>17,510</b>	<b>17,157</b>	<b>16,952</b>	<b>17,618</b>	<b>19,388</b>		
C10B	Genital herpes simplex – recurrence	Male (all)	5,642	5,560	5,983	6,095	6,204	6,376	6,373	6,072	6,250	6,597	
		-of which MSM	389	356	396	442	397	391	462	433	498	497	
		Female	6,741	6,798	7,226	7,345	8,049	8,142	8,009	7,724	8,013	8,387	
	<b>Total</b>	<b>12,383</b>	<b>12,358</b>	<b>13,209</b>	<b>13,440</b>	<b>14,253</b>	<b>14,518</b>	<b>14,382</b>	<b>13,796</b>	<b>14,263</b>	<b>14,984</b>		
C11A	Genital warts – first attack	Male (all)	30,239	30,782	31,846	31,975	32,700	33,987	34,642	36,418	36,368	37,698	
		-of which MSM	1,472	1,501	1,565	1,673	1,771	1,963	2,108	2,032	2,258	2,352	
		Female	28,472	28,899	29,311	28,686	29,723	29,951	30,637	31,799	32,333	33,290	
	<b>Total</b>	<b>58,711</b>	<b>59,681</b>	<b>61,157</b>	<b>60,661</b>	<b>62,423</b>	<b>63,938</b>	<b>65,279</b>	<b>68,217</b>	<b>68,701</b>	<b>70,988</b>		
C11B	Genital warts – recurrence	Male (all)	21,180	21,847	22,141	22,226	22,579	22,061	21,813	22,228	23,288	24,535	
		-of which MSM	1,227	1,228	1,211	1,213	1,376	1,387	1,548	1,615	1,544	1,719	
		Female	12,048	12,448	12,293	12,419	12,170	12,137	12,501	12,792	13,710	14,897	
	<b>Total</b>	<b>33,228</b>	<b>34,295</b>	<b>34,434</b>	<b>34,645</b>	<b>34,749</b>	<b>34,198</b>	<b>34,314</b>	<b>35,020</b>	<b>36,998</b>	<b>39,432</b>		
C11C	Genital warts – re-registered cases†	Male (all)	7,767	8,942	9,314	9,047	8,988	8,464	8,803	8,499	8,778	9,094	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	6,776	7,408	7,597	7,219	7,148	6,517	6,616	6,450	6,810	6,868	
	<b>Total</b>	<b>14,543</b>	<b>16,350</b>	<b>16,911</b>	<b>16,266</b>	<b>16,136</b>	<b>14,981</b>	<b>15,419</b>	<b>14,949</b>	<b>15,588</b>	<b>15,962</b>		
C12	Molluscum contagiosum	Male (all)	3,985	4,363	4,763	5,100	5,571	6,187	6,940	8,045	8,846	9,604	
		-of which MSM	281	209	215	206	225	209	250	258	286	300	
		Female	2,212	2,373	2,637	2,691	3,003	3,250	3,485	3,892	4,239	4,495	
	<b>Total</b>	<b>6,197</b>	<b>6,736</b>	<b>7,400</b>	<b>7,791</b>	<b>8,574</b>	<b>9,437</b>	<b>10,425</b>	<b>11,937</b>	<b>13,085</b>	<b>14,099</b>		
C13	Antigen positive viral hepatitis B	Male (all)	618	551	527	635	704	931	0	0	0	0	
		-of which MSM	139	106	102	128	155	195	0	0	0	0	
		Female	179	203	249	230	352	472	0	0	0	0	
	<b>Total</b>	<b>797</b>	<b>754</b>	<b>776</b>	<b>865</b>	<b>1,056</b>	<b>1,403</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>		
C13A*	Viral hepatitis B (HbsAg positive): first diagnosis**	Male (all)	-	-	-	-	-	-	602	649	637	634	
		-of which MSM	-	-	-	-	-	-	111	88	90	52	
		Female	-	-	-	-	-	-	271	325	325	331	
	<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>873</b>	<b>974</b>	<b>962</b>	<b>965</b>		

England: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
C13B*	**number of which were acute viral hepatitis B	Male (all)	-	-	-	-	-	-	46	54	44	37
		-of which MSM	-	-	-	-	-	-	14	19	14	7
		Female	-	-	-	-	-	-	10	12	25	22
		<b>Total</b>	-	-	-	-	-	-	<b>56</b>	<b>66</b>	<b>69</b>	<b>59</b>
C13C*	Viral hepatitis B: subsequent presentation	Male (all)	-	-	-	-	-	-	342	459	414	426
		-of which MSM	-	-	-	-	-	-	121	205	206	226
		Female	-	-	-	-	-	-	150	168	143	187
		<b>Total</b>	-	-	-	-	-	-	<b>492</b>	<b>627</b>	<b>557</b>	<b>613</b>
C14*	Viral hepatitis C: first diagnosis (previous to 2003 C14 was other viral hepatitis)	Male (all)	1,084	1,033	918	929	918	1,044	1,004	1,039	941	850
		-of which MSM	141	129	83	103	104	140	110	123	115	111
		Female	420	431	425	422	380	484	462	438	398	346
		<b>Total</b>	<b>1,504</b>	<b>1,464</b>	<b>1,343</b>	<b>1,351</b>	<b>1,298</b>	<b>1,528</b>	<b>1,466</b>	<b>1,477</b>	<b>1,339</b>	<b>1,196</b>
E1A	Asymptomatic HIV infection – first presentation	Male (all)	1,131	1,104	1,063	1,184	1,655	2,302	2,656	2,769	2,852	2,661
		-of which MSM	622	546	518	590	740	737	1,094	1,201	1,295	1,211
		Female	357	351	573	670	1,109	1,977	2,106	2,054	2,036	1,778
		<b>Total</b>	<b>1,488</b>	<b>1,455</b>	<b>1,636</b>	<b>1,854</b>	<b>2,764</b>	<b>4,279</b>	<b>4,762</b>	<b>4,823</b>	<b>4,888</b>	<b>4,439</b>
E1B*	Asymptomatic HIV infection – subsequent presentation	Male (all)	5,791	6,165	6,505	7,588	8,375	10,058	0	18	0	0
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	1,514	1,785	2,096	2,860	3,792	5,532	0	16	0	0
<b>Total</b>	<b>7,305</b>	<b>7,950</b>	<b>8,601</b>	<b>10,448</b>	<b>12,167</b>	<b>15,590</b>	<b>0</b>	<b>34</b>	<b>0</b>	<b>0</b>		
E1BE2B*	Subsequent HIV presentation (not AIDS)	Male (all)	-	-	-	-	-	-	25,773	30,935	37,629	39,204
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	-	-	-	-	-	-	-	12,209	16,402	20,525
<b>Total</b>	-	-	-	-	-	-	-	<b>37,982</b>	<b>47,337</b>	<b>58,154</b>	<b>60,894</b>	
E2A	HIV infection with symptoms, not AIDS – first presentation	Male (all)	888	567	514	470	641	744	664	669	735	631
		-of which MSM	532	285	278	222	300	244	263	246	253	231
		Female	226	191	195	198	326	445	441	385	442	350
		<b>Total</b>	<b>1,114</b>	<b>758</b>	<b>709</b>	<b>668</b>	<b>967</b>	<b>1,189</b>	<b>1,105</b>	<b>1,054</b>	<b>1,177</b>	<b>981</b>
E2B*	HIV infection with symptoms, not AIDS – subsequent presentation	Male (all)	6,633	7,744	7,788	8,880	9,139	9,265	0	3	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	1,215	1,694	1,854	2,230	2,623	3,310	0	2	0	0
<b>Total</b>	<b>7,848</b>	<b>9,438</b>	<b>9,642</b>	<b>11,110</b>	<b>11,762</b>	<b>12,575</b>	<b>0</b>	<b>5</b>	<b>0</b>	<b>0</b>		
E3A*	AIDS – first presentation	Male (all)	663	427	377	360	430	436	0	0	0	0
		-of which MSM	351	188	151	178	167	155	0	0	0	0
		Female	154	127	110	139	214	227	0	0	0	0
		<b>Total</b>	<b>817</b>	<b>554</b>	<b>487</b>	<b>499</b>	<b>644</b>	<b>663</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
E3A1*	AIDS: first presentation - new HIV diagnosis	Male (all)	-	-	-	-	-	-	176	217	226	189
		-of which MSM	-	-	-	-	-	-	69	61	76	63
		Female	-	-	-	-	-	-	137	116	150	90
<b>Total</b>	-	-	-	-	-	-	-	<b>313</b>	<b>333</b>	<b>376</b>	<b>279</b>	
E3A2*	AIDS: first presentation - HIV diagnosed previously	Male (all)	-	-	-	-	-	-	236	153	161	158
		-of which MSM	-	-	-	-	-	-	94	74	60	84
		Female	-	-	-	-	-	-	133	63	70	74
		<b>Total</b>	-	-	-	-	-	-	<b>369</b>	<b>216</b>	<b>231</b>	<b>232</b>

England: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	
E3B	AIDS – subsequent presentation	Male (all)	4,591	5,261	5,396	6,119	6,683	7,605	9,539	10,273	11,637	11,601	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	763	1,071	1,229	1,551	2,001	2,584	3,999	4,319	4,965	5,148	5,148
	<b>Total</b>	<b>5,354</b>	<b>6,332</b>	<b>6,625</b>	<b>7,670</b>	<b>8,684</b>	<b>10,189</b>	<b>13,538</b>	<b>14,592</b>	<b>16,602</b>	<b>16,749</b>	<b>16,749</b>	
D2A	Urinary tract infection	Male (all)	1,836	1,927	2,040	1,910	1,981	2,522	2,483	2,479	2,028	2,131	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	8,757	8,711	9,064	9,351	9,431	9,152	8,717	9,772	9,351	9,854	9,854
	<b>Total</b>	<b>10,593</b>	<b>10,638</b>	<b>11,104</b>	<b>11,261</b>	<b>11,412</b>	<b>11,674</b>	<b>11,200</b>	<b>12,251</b>	<b>11,379</b>	<b>11,985</b>	<b>11,985</b>	
D2B	Other conditions requiring treatment at GUM clinic	Male (all)	44,724	50,924	52,418	54,692	54,839	57,505	64,250	64,697	66,904	68,973	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	46,209	48,031	48,791	53,560	54,402	54,721	53,126	54,501	55,624	57,330	57,330
	<b>Total</b>	<b>90,933</b>	<b>98,955</b>	<b>101,209</b>	<b>108,252</b>	<b>109,241</b>	<b>112,226</b>	<b>117,376</b>	<b>119,198</b>	<b>122,528</b>	<b>126,303</b>	<b>126,303</b>	
D3	Other episodes not requiring treatment	Male (all)	89,765	97,722	100,901	106,796	125,321	141,931	133,675	160,686	188,501	206,577	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	99,557	107,328	110,295	113,953	131,498	146,874	135,640	158,352	190,194	205,483	205,483
	<b>Total</b>	<b>189,322</b>	<b>205,050</b>	<b>211,196</b>	<b>220,749</b>	<b>256,819</b>	<b>288,805</b>	<b>269,315</b>	<b>319,038</b>	<b>378,695</b>	<b>412,060</b>	<b>412,060</b>	
P1A	HIV antibody counselling - with testing	Male (all)	67,602	71,699	73,635	83,890	109,903	145,623	48,164	42,841	39,940	34,154	
		-of which MSM	10,144	10,917	10,869	12,125	15,980	18,223	8,154	7,455	7,746	7,211	
		Female	54,018	57,599	59,051	67,569	92,977	129,933	37,024	30,537	29,874	25,516	
		<b>Total</b>	<b>121,620</b>	<b>129,298</b>	<b>132,686</b>	<b>151,459</b>	<b>202,880</b>	<b>275,556</b>	<b>85,188</b>	<b>73,378</b>	<b>69,814</b>	<b>59,670</b>	
P1B	HIV antibody counselling - without testing	Male (all)	11,496	12,582	12,962	14,326	19,265	42,360	95,065	116,163	112,939	109,031	
		-of which MSM	956	1,089	1,396	1,137	1,643	3,102	5,937	6,237	6,278	6,245	
		Female	11,275	11,775	12,432	13,612	19,130	47,485	109,531	133,388	131,478	129,178	
		<b>Total</b>	<b>22,771</b>	<b>24,357</b>	<b>25,394</b>	<b>27,938</b>	<b>38,395</b>	<b>89,845</b>	<b>204,596</b>	<b>249,551</b>	<b>244,417</b>	<b>238,209</b>	
P2	Hepatitis B vaccination	Male (all)	9,301	9,847	9,989	10,885	11,859	13,313	14,464	15,858	15,516	16,053	
		-of which MSM	4,659	4,835	4,707	5,218	5,850	6,604	7,838	8,348	8,432	8,403	
		Female	2,317	2,597	2,491	2,630	3,142	3,909	4,092	4,982	5,253	5,650	
	<b>Total</b>	<b>11,618</b>	<b>12,444</b>	<b>12,480</b>	<b>13,515</b>	<b>15,001</b>	<b>17,222</b>	<b>18,556</b>	<b>20,840</b>	<b>20,769</b>	<b>21,703</b>		
P3	Family Planning	Male (all)	-	-	-	-	-	-	-	-	-	-	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	25,902	31,801	30,263	32,771	33,646	31,444	32,774	33,858	34,563	37,851	
	<b>Total</b>	<b>25,902</b>	<b>31,801</b>	<b>30,263</b>	<b>32,771</b>	<b>33,646</b>	<b>31,444</b>	<b>32,774</b>	<b>33,858</b>	<b>34,563</b>	<b>37,851</b>		
P4A	Cervical cytology - minor abnormality	Male (all)	-	-	-	-	-	-	-	-	-	-	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	10,827	9,387	7,583	6,214	4,744	3,663	5,212	3,351	1,676	1,412	
	<b>Total</b>	<b>10,827</b>	<b>9,387</b>	<b>7,583</b>	<b>6,214</b>	<b>4,744</b>	<b>3,663</b>	<b>5,212</b>	<b>3,351</b>	<b>1,676</b>	<b>1,412</b>		
P4B	Cervical cytology - major abnormality	Male (all)	-	-	-	-	-	-	-	-	-	-	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	1,660	1,346	1,184	1,120	1,024	751	912	793	383	289	
	<b>Total</b>	<b>1,660</b>	<b>1,346</b>	<b>1,184</b>	<b>1,120</b>	<b>1,024</b>	<b>751</b>	<b>912</b>	<b>793</b>	<b>383</b>	<b>289</b>		

England: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	
S1*	Sexual health screen (no HIV antibody test)	Male (all)	-	-	-	-	-	-	141,976	142,890	135,850	133,618	
		-of which MSM	-	-	-	-	-	-	9,684	9,833	10,731	11,911	
		Female	-	-	-	-	-	-	176,335	174,285	167,932	163,435	
		<b>Total</b>	-	-	-	-	-	-	<b>318,311</b>	<b>317,175</b>	<b>303,782</b>	<b>297,053</b>	
S2*	HIV antibody test and sexual health screen	Male (all)	-	-	-	-	-	-	158,950	208,016	255,017	296,093	
		-of which MSM	-	-	-	-	-	-	15,882	18,964	22,812	27,123	
		Female	-	-	-	-	-	-	156,028	201,819	251,341	289,949	
		<b>Total</b>	-	-	-	-	-	-	<b>314,978</b>	<b>409,835</b>	<b>506,358</b>	<b>586,042</b>	
<b>Total new STI diagnoses</b>			Male (all)	123,048	130,123	138,706	151,486	161,650	172,857	182,533	191,343	194,553	200,403
			-of which MSM	9,455	9,292	9,758	11,925	14,262	14,416	16,287	16,458	18,253	19,204
			Female	85,125	89,565	95,703	103,695	110,737	119,053	129,039	134,440	133,441	134,720
			<b>Total</b>	<b>208,173</b>	<b>219,688</b>	<b>234,409</b>	<b>255,181</b>	<b>272,387</b>	<b>291,910</b>	<b>311,572</b>	<b>325,783</b>	<b>327,994</b>	<b>335,123</b>
<b>Total other STI diagnoses</b>			Male (all)	67,228	72,376	77,248	83,561	89,441	96,061	106,053	114,278	125,254	128,323
			-of which MSM	3,222	2,937	3,280	3,584	4,308	4,837	5,699	6,026	6,547	7,321
			Female	54,105	58,386	61,487	65,469	71,024	75,098	79,232	85,802	93,842	95,972
			<b>Total</b>	<b>121,333</b>	<b>130,762</b>	<b>138,735</b>	<b>149,030</b>	<b>160,465</b>	<b>171,159</b>	<b>185,285</b>	<b>200,080</b>	<b>219,096</b>	<b>224,295</b>
<b>Total other GUM clinic diagnoses</b>			Male (all)	73,200	79,315	80,127	81,838	82,700	86,058	92,231	92,585	93,459	96,423
			-of which MSM	280	235	185	231	259	335	356	435	425	396
			Female	193,199	197,469	201,048	210,102	218,564	222,907	219,882	215,441	210,064	214,472
			<b>Total</b>	<b>266,399</b>	<b>276,784</b>	<b>281,175</b>	<b>291,940</b>	<b>301,264</b>	<b>308,965</b>	<b>312,113</b>	<b>308,026</b>	<b>303,523</b>	<b>310,895</b>
<b>Total services provided</b>			Male (all)	178,164	191,850	197,487	215,897	266,348	343,227	592,294	686,454	747,763	795,526
			-of which MSM	15,759	16,841	16,972	18,480	23,473	27,929	47,495	50,837	55,999	60,893
			Female	193,069	211,100	214,532	230,535	280,393	359,645	651,424	737,221	810,635	857,062
			<b>Total</b>	<b>371,233</b>	<b>402,950</b>	<b>412,019</b>	<b>446,432</b>	<b>546,741</b>	<b>702,872</b>	<b>1,243,718</b>	<b>1,423,675</b>	<b>1,558,398</b>	<b>1,652,588</b>

Source: HPA Centre for Infections

\* KC60 codes were created/revised in quarter 3, 2002

† previous diagnosis of C11a or C11b treated for more than 3 months

- data not available/applicable



Wales:

Number of new episodes seen at genitourinary medicine clinics by sex, 1997 - 2006

KC60 codes and conditions			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
A1,A2	Primary and secondary infectious syphilis	Male (all)	2	1	3	5	6	13	47	43	39	29
		-of which MSM	1	0	0	4	3	10	29	33	20	21
		Female	1	0	0	0	2	0	3	1	4	5
		<b>Total</b>	<b>3</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>8</b>	<b>13</b>	<b>50</b>	<b>44</b>	<b>43</b>	<b>34</b>
A3	Early latent syphilis (first 2 years)	Male (all)	2	1	2	0	3	15	12	19	13	9
		-of which MSM	1	1	0	0	0	5	3	11	10	2
		Female	1	0	2	0	0	2	2	2	3	1
		<b>Total</b>	<b>3</b>	<b>1</b>	<b>4</b>	<b>0</b>	<b>3</b>	<b>17</b>	<b>14</b>	<b>21</b>	<b>16</b>	<b>10</b>
A4,A5,A6	Other acquired syphilis	Male (all)	11	12	15	13	16	23	13	23	21	21
		-of which MSM	1	1	2	3	0	5	3	6	9	7
		Female	2	5	4	4	6	12	6	11	9	8
		<b>Total</b>	<b>13</b>	<b>17</b>	<b>19</b>	<b>17</b>	<b>22</b>	<b>35</b>	<b>19</b>	<b>34</b>	<b>30</b>	<b>29</b>
A7	Congenital syphilis, aged under 2	Male (all)	0	0	0	0	0	0	0	1	0	0
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	0	0	0	0	0	0	0	0	0	0
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>
A8	Congenital syphilis, aged 2 or over	Male (all)	0	0	2	0	0	2	0	0	0	0
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	0	0	0	0	0	0	0	1	0	0
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>
A9	Epidemiological treatment of suspected syphilis	Male (all)	0	0	0	0	0	2	1	6	5	4
		-of which MSM	0	0	0	0	0	0	1	5	1	3
		Female	0	0	0	0	0	2	1	1	0	1
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>4</b>	<b>2</b>	<b>7</b>	<b>5</b>	<b>5</b>
B1,B2	Uncomplicated gonorrhoea	Male (all)	147	151	204	316	300	303	398	449	382	340
		-of which MSM	24	15	24	61	74	58	74	91	87	61
		Female	61	82	103	157	131	141	187	216	152	140
		<b>Total</b>	<b>208</b>	<b>233</b>	<b>307</b>	<b>473</b>	<b>431</b>	<b>444</b>	<b>585</b>	<b>665</b>	<b>534</b>	<b>480</b>
B3	Gonococcal ophthalmia neonatorum	Male (all)	0	0	1	0	0	0	1	0	1	0
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	1	0	0	0	0	3	0	0	0	0
		<b>Total</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>3</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>0</b>
B4	Epidemiological treatment of suspected gonorrhoea	Male (all)	27	36	39	71	77	56	80	111	103	89
		-of which MSM	11	5	8	12	19	11	19	21	20	20
		Female	34	37	61	68	60	90	88	95	85	95
		<b>Total</b>	<b>61</b>	<b>73</b>	<b>100</b>	<b>139</b>	<b>137</b>	<b>146</b>	<b>168</b>	<b>206</b>	<b>188</b>	<b>184</b>
B5	Gonococcal complications	Male (all)	1	1	4	1	3	2	4	3	2	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	2	3	3	11	4	4	7	6	3	5
		<b>Total</b>	<b>3</b>	<b>4</b>	<b>7</b>	<b>12</b>	<b>7</b>	<b>6</b>	<b>11</b>	<b>9</b>	<b>5</b>	<b>5</b>

Wales: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
C1,C2,C3	Chancroid/LGV/Donovanosis	Male (all)	1	0	4	0	0	1	1	0	2	2
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	0	0	0	0	0	1	3	1	1	0
		<b>Total</b>	<b>1</b>	<b>0</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>4</b>	<b>1</b>	<b>3</b>	<b>2</b>
C4A,C4C	Uncomplicated chlamydial infection	Male (all)	526	603	738	988	1,124	1,177	1,354	1,577	1,903	1,794
		-of which MSM	3	8	6	20	34	31	44	43	45	48
		Female	664	980	1,247	1,402	1,640	1,722	1,759	1,850	2,036	1,935
		<b>Total</b>	<b>1,190</b>	<b>1,583</b>	<b>1,985</b>	<b>2,390</b>	<b>2,764</b>	<b>2,899</b>	<b>3,113</b>	<b>3,427</b>	<b>3,939</b>	<b>3,729</b>
C4B	Complicated chlamydial infection	Male (all)	10	11	22	12	22	18	31	23	25	17
		-of which MSM	0	0	0	0	0	1	0	1	2	0
		Female	71	59	72	121	113	98	94	107	99	87
		<b>Total</b>	<b>81</b>	<b>70</b>	<b>94</b>	<b>133</b>	<b>135</b>	<b>116</b>	<b>125</b>	<b>130</b>	<b>124</b>	<b>104</b>
C4D	Chlamydial ophthalmia neonatorum	Male (all)	0	0	2	0	0	1	1	0	2	1
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	0	0	0	4	0	0	0	0	1	0
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>4</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>3</b>	<b>1</b>
C4E	Epidemiological treatment of suspected chlamydial infection	Male (all)	341	558	704	713	793	903	830	1,015	1,042	1,118
		-of which MSM	24	16	23	50	66	39	45	59	64	42
		Female	254	457	509	502	424	555	531	702	718	752
		<b>Total</b>	<b>595</b>	<b>1,015</b>	<b>1,213</b>	<b>1,215</b>	<b>1,217</b>	<b>1,458</b>	<b>1,361</b>	<b>1,717</b>	<b>1,760</b>	<b>1,870</b>
C4H*	Uncomplicated non-gonococcal/non-spec urethritis males(females) treatment of mucopurulent cervicitis	Male (all)	1,165	1,142	1,387	1,587	1,627	1,751	2,007	2,293	2,391	2,180
		-of which MSM	22	22	27	48	57	88	86	80	79	75
		Female	0	0	0	0	0	0	142	256	397	535
		<b>Total</b>	<b>1,165</b>	<b>1,142</b>	<b>1,387</b>	<b>1,587</b>	<b>1,627</b>	<b>1,751</b>	<b>2,149</b>	<b>2,549</b>	<b>2,788</b>	<b>2,715</b>
C4I	Epidemiological treatment of NSGI	Male (all)	210	167	202	170	172	166	183	178	188	257
		-of which MSM	4	3	2	7	10	15	13	15	11	13
		Female	501	446	600	801	774	719	643	648	598	729
		<b>Total</b>	<b>711</b>	<b>613</b>	<b>802</b>	<b>971</b>	<b>946</b>	<b>885</b>	<b>826</b>	<b>826</b>	<b>786</b>	<b>986</b>
C5	Complicated infection non-gonococcal/non-chlamydial	Male (all)	65	62	82	82	86	80	77	102	119	134
		-of which MSM	1	0	2	0	1	2	2	2	4	8
		Female	293	237	301	384	317	280	337	386	394	438
		<b>Total</b>	<b>358</b>	<b>299</b>	<b>383</b>	<b>466</b>	<b>403</b>	<b>360</b>	<b>414</b>	<b>488</b>	<b>513</b>	<b>572</b>
C6A	Trichomoniasis	Male (all)	8	3	6	1	12	4	2	2	6	6
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	84	119	84	77	82	62	48	51	72	58
		<b>Total</b>	<b>92</b>	<b>122</b>	<b>90</b>	<b>78</b>	<b>94</b>	<b>66</b>	<b>50</b>	<b>53</b>	<b>78</b>	<b>64</b>
C6B	Anaerobic/bacterial vaginosis & anaerobic balanitis	Male (all)	32	38	30	27	21	33	44	62	79	91
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	1,478	1,517	1,545	1,790	1,810	2,064	2,175	2,545	2,873	2,906
		<b>Total</b>	<b>1,510</b>	<b>1,555</b>	<b>1,575</b>	<b>1,817</b>	<b>1,831</b>	<b>2,097</b>	<b>2,219</b>	<b>2,607</b>	<b>2,952</b>	<b>2,997</b>
C6C	Other vaginosis/vaginitis/balanitis	Male (all)	453	452	512	484	581	499	591	651	706	616
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	112	137	140	181	237	140	152	137	144	112
		<b>Total</b>	<b>565</b>	<b>589</b>	<b>652</b>	<b>665</b>	<b>818</b>	<b>639</b>	<b>743</b>	<b>788</b>	<b>850</b>	<b>728</b>

Wales: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	
C7A	Genital candidosis	Male (all)	442	399	329	272	299	232	242	254	400	375	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	2,078	2,036	1,978	1,929	1,947	1,967	1,944	2,270	2,629	2,738	
	<b>Total</b>	<b>2,520</b>	<b>2,435</b>	<b>2,307</b>	<b>2,201</b>	<b>2,246</b>	<b>2,199</b>	<b>2,186</b>	<b>2,524</b>	<b>3,029</b>	<b>3,113</b>		
C7B	Epidemiological treatment of C6 & C7	Male (all)	60	49	58	31	24	82	62	64	61	52	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	73	29	70	25	23	58	61	57	67	42	
	<b>Total</b>	<b>133</b>	<b>78</b>	<b>128</b>	<b>56</b>	<b>47</b>	<b>140</b>	<b>123</b>	<b>121</b>	<b>128</b>	<b>94</b>		
C8,C9	Scabies/pediculosis pubis	Male (all)	118	85	107	155	115	82	69	73	80	65	
		-of which MSM	10	7	8	25	18	13	10	16	21	15	
		Female	43	33	32	36	24	28	11	11	7	13	
	<b>Total</b>	<b>161</b>	<b>118</b>	<b>139</b>	<b>191</b>	<b>139</b>	<b>110</b>	<b>80</b>	<b>84</b>	<b>87</b>	<b>78</b>		
C10A	Genital herpes simplex – first attack	Male (all)	200	155	190	175	202	215	207	205	225	233	
		-of which MSM	2	0	5	13	10	10	5	9	6	5	
		Female	297	275	316	322	340	389	398	411	417	413	
	<b>Total</b>	<b>497</b>	<b>430</b>	<b>506</b>	<b>497</b>	<b>542</b>	<b>604</b>	<b>605</b>	<b>616</b>	<b>642</b>	<b>646</b>		
C10B	Genital herpes simplex – recurrence	Male (all)	129	106	120	125	147	156	157	183	201	179	
		-of which MSM	1	4	6	4	10	10	4	8	10	8	
		Female	110	123	127	156	161	200	205	199	207	195	
	<b>Total</b>	<b>239</b>	<b>229</b>	<b>247</b>	<b>281</b>	<b>308</b>	<b>356</b>	<b>362</b>	<b>382</b>	<b>408</b>	<b>374</b>		
C11A	Genital warts – first attack	Male (all)	1,592	1,593	1,670	1,662	1,744	1,752	1,730	1,858	1,949	1,887	
		-of which MSM	15	22	30	34	49	55	56	63	63	59	
		Female	1,550	1,525	1,509	1,587	1,594	1,523	1,619	1,611	1,794	1,823	
	<b>Total</b>	<b>3,142</b>	<b>3,118</b>	<b>3,179</b>	<b>3,249</b>	<b>3,338</b>	<b>3,275</b>	<b>3,349</b>	<b>3,469</b>	<b>3,743</b>	<b>3,710</b>		
C11B	Genital warts – recurrence	Male (all)	929	986	959	1,033	1,041	990	932	977	913	935	
		-of which MSM	8	9	14	14	21	30	26	29	33	22	
		Female	503	491	536	537	545	550	446	556	540	532	
	<b>Total</b>	<b>1,432</b>	<b>1,477</b>	<b>1,495</b>	<b>1,570</b>	<b>1,586</b>	<b>1,540</b>	<b>1,378</b>	<b>1,533</b>	<b>1,453</b>	<b>1,467</b>		
C11C	Genital warts – re-registered cases†	Male (all)	283	368	441	367	366	318	384	402	351	420	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	208	331	348	355	309	235	310	326	313	347	
	<b>Total</b>	<b>491</b>	<b>699</b>	<b>789</b>	<b>722</b>	<b>675</b>	<b>553</b>	<b>694</b>	<b>728</b>	<b>664</b>	<b>767</b>		
C12	Molluscum contagiosum	Male (all)	137	113	132	153	150	158	172	220	247	258	
		-of which MSM	2	1	3	0	2	2	4	5	7	4	
		Female	101	75	87	89	95	88	114	143	146	164	
	<b>Total</b>	<b>238</b>	<b>188</b>	<b>219</b>	<b>242</b>	<b>245</b>	<b>246</b>	<b>286</b>	<b>363</b>	<b>393</b>	<b>422</b>		
C13	Antigen positive viral hepatitis B	Male (all)	21	13	9	16	16	17	0	1	0	0	
		-of which MSM	3	1	0	2	2	5	0	0	0	0	
		Female	12	3	2	1	5	12	0	0	0	0	
	<b>Total</b>	<b>33</b>	<b>16</b>	<b>11</b>	<b>17</b>	<b>21</b>	<b>29</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>		
C13A*	Viral hepatitis B (HbsAg positive): first diagnosis**	Male (all)	-	-	-	-	-	-	11	17	15	14	
		-of which MSM	-	-	-	-	-	-	2	4	1	1	
		Female	-	-	-	-	-	-	5	2	4	1	
	<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>16</b>	<b>19</b>	<b>19</b>	<b>15</b>		

Wales: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
C13B*	**number of which were acute viral hepatitis B	Male (all)	-	-	-	-	-	-	1	0	2	0
		-of which MSM	-	-	-	-	-	-	0	0	0	0
		Female	-	-	-	-	-	-	1	0	4	4
		<b>Total</b>	-	-	-	-	-	-	<b>2</b>	<b>0</b>	<b>6</b>	<b>4</b>
C13C*	Viral hepatitis B: subsequent presentation	Male (all)	-	-	-	-	-	-	2	2	3	3
		-of which MSM	-	-	-	-	-	-	0	0	1	1
		Female	-	-	-	-	-	-	1	1	22	18
		<b>Total</b>	-	-	-	-	-	-	<b>3</b>	<b>3</b>	<b>25</b>	<b>21</b>
C14*	Viral hepatitis C: fist diagnosis (previous to 2003 C14 was other viral hepatitis)	Male (all)	35	33	37	47	34	51	46	42	34	46
		-of which MSM	1	3	0	3	1	5	0	2	1	1
		Female	11	25	25	23	16	16	26	17	13	18
		<b>Total</b>	<b>46</b>	<b>58</b>	<b>62</b>	<b>70</b>	<b>50</b>	<b>67</b>	<b>72</b>	<b>59</b>	<b>47</b>	<b>64</b>
E1A	Asymptomatic HIV infection – first presentation	Male (all)	22	15	17	27	28	25	31	43	49	54
		-of which MSM	11	8	13	19	13	18	18	22	23	25
		Female	5	4	3	9	15	13	29	15	14	18
		<b>Total</b>	<b>27</b>	<b>19</b>	<b>20</b>	<b>36</b>	<b>43</b>	<b>38</b>	<b>60</b>	<b>58</b>	<b>63</b>	<b>72</b>
E1B*	Asymptomatic HIV infection – subsequent presentation	Male (all)	133	144	160	178	148	158	4	3	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	16	17	28	27	34	57	0	0	0	0
		<b>Total</b>	<b>149</b>	<b>161</b>	<b>188</b>	<b>205</b>	<b>182</b>	<b>215</b>	<b>4</b>	<b>3</b>	<b>0</b>	<b>0</b>
E1BE2B*	Subsequent HIV presentation (not AIDS)	Male (all)	-	-	-	-	-	-	177	347	686	764
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	-	-	-	-	-	-	62	128	232	266
		<b>Total</b>	-	-	-	-	-	-	<b>239</b>	<b>475</b>	<b>918</b>	<b>1,030</b>
E2A	HIV infection with symptoms, not AIDS – first presentation	Male (all)	18	13	8	24	34	23	17	17	15	16
		-of which MSM	4	8	2	16	24	18	7	7	12	9
		Female	3	1	0	8	6	12	17	8	6	9
		<b>Total</b>	<b>21</b>	<b>14</b>	<b>8</b>	<b>32</b>	<b>40</b>	<b>35</b>	<b>34</b>	<b>25</b>	<b>21</b>	<b>25</b>
E2B*	HIV infection with symptoms, not AIDS – subsequent presentation	Male (all)	92	102	124	169	265	273	5	11	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	14	24	27	32	48	62	0	3	0	0
		<b>Total</b>	<b>106</b>	<b>126</b>	<b>151</b>	<b>201</b>	<b>313</b>	<b>335</b>	<b>5</b>	<b>14</b>	<b>0</b>	<b>0</b>
E3A*	AIDS – first presentation	Male (all)	3	9	17	8	16	22	0	1	0	0
		-of which MSM	2	4	7	3	7	14	0	0	0	0
		Female	6	4	1	1	1	9	0	0	0	0
		<b>Total</b>	<b>9</b>	<b>13</b>	<b>18</b>	<b>9</b>	<b>17</b>	<b>31</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>
E3A1*	AIDS: first presentation - new HIV diagnosis	Male (all)	-	-	-	-	-	-	4	5	3	2
		-of which MSM	-	-	-	-	-	-	2	1	0	0
		Female	-	-	-	-	-	-	5	2	0	0
		<b>Total</b>	-	-	-	-	-	-	<b>9</b>	<b>7</b>	<b>3</b>	<b>2</b>
E3A2*	AIDS: first presentation - HIV diagnosed previously	Male (all)	-	-	-	-	-	-	0	0	0	0
		-of which MSM	-	-	-	-	-	-	0	0	0	0
		Female	-	-	-	-	-	-	2	2	0	0
		<b>Total</b>	-	-	-	-	-	-	<b>2</b>	<b>2</b>	<b>0</b>	<b>0</b>

Wales: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	
E3B	AIDS – subsequent presentation	Male (all)	47	48	109	168	198	220	125	166	174	169	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	8	4	29	42	44	51	30	44	41	38	
	<b>Total</b>	<b>55</b>	<b>52</b>	<b>138</b>	<b>210</b>	<b>242</b>	<b>271</b>	<b>155</b>	<b>210</b>	<b>215</b>	<b>207</b>		
D2A	Urinary tract infection	Male (all)	31	28	24	27	17	15	31	38	43	39	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	95	58	96	90	94	96	114	159	138	150	
	<b>Total</b>	<b>126</b>	<b>86</b>	<b>120</b>	<b>117</b>	<b>111</b>	<b>111</b>	<b>145</b>	<b>197</b>	<b>181</b>	<b>189</b>		
D2B	Other conditions requiring treatment at GUM clinic	Male (all)	774	834	918	997	1,013	1,088	1,173	1,334	1,452	1,467	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	732	743	704	755	654	899	1,077	1,202	1,237	1,315	
	<b>Total</b>	<b>1,506</b>	<b>1,577</b>	<b>1,622</b>	<b>1,752</b>	<b>1,667</b>	<b>1,987</b>	<b>2,250</b>	<b>2,536</b>	<b>2,689</b>	<b>2,782</b>		
D3	Other episodes not requiring treatment	Male (all)	2,506	2,613	2,669	2,860	3,301	3,918	3,822	4,531	5,492	5,862	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	2,143	2,267	2,347	2,587	2,990	3,404	3,067	3,834	4,467	4,589	
	<b>Total</b>	<b>4,649</b>	<b>4,880</b>	<b>5,016</b>	<b>5,447</b>	<b>6,291</b>	<b>7,322</b>	<b>6,889</b>	<b>8,365</b>	<b>9,959</b>	<b>10,451</b>		
P1A	HIV antibody counselling - with testing	Male (all)	1,819	1,742	1,785	1,846	2,466	3,624	1,057	997	969	967	
		-of which MSM	159	150	206	285	356	524	224	155	135	127	
		Female	1,457	1,453	1,336	1,386	1,833	2,915	617	671	604	611	
	<b>Total</b>	<b>3,276</b>	<b>3,195</b>	<b>3,121</b>	<b>3,232</b>	<b>4,299</b>	<b>6,539</b>	<b>1,674</b>	<b>1,668</b>	<b>1,573</b>	<b>1,578</b>		
P1B	HIV antibody counselling - without testing	Male (all)	402	363	302	299	567	2,179	3,402	4,348	4,784	4,813	
		-of which MSM	7	19	14	28	55	164	170	139	131	127	
		Female	363	318	236	241	512	2,145	3,179	4,149	4,432	4,464	
	<b>Total</b>	<b>765</b>	<b>681</b>	<b>538</b>	<b>540</b>	<b>1,079</b>	<b>4,324</b>	<b>6,581</b>	<b>8,497</b>	<b>9,216</b>	<b>9,277</b>		
P2	Hepatitis B vaccination	Male (all)	226	257	198	221	295	393	313	355	376	393	
		-of which MSM	99	94	154	108	139	217	160	192	192	202	
		Female	35	56	70	68	60	81	108	134	138	150	
	<b>Total</b>	<b>261</b>	<b>313</b>	<b>268</b>	<b>289</b>	<b>355</b>	<b>474</b>	<b>421</b>	<b>489</b>	<b>514</b>	<b>543</b>		
P3	Family Planning	Male (all)	-	-	-	-	-	-	-	-	-	-	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	258	284	349	522	277	395	295	283	367	384	
	<b>Total</b>	<b>258</b>	<b>284</b>	<b>349</b>	<b>522</b>	<b>277</b>	<b>395</b>	<b>295</b>	<b>283</b>	<b>367</b>	<b>384</b>		
P4A	Cervical cytology - minor abnormality	Male (all)	-	-	-	-	-	-	-	-	-	-	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	269	275	174	132	84	85	72	74	91	102	
	<b>Total</b>	<b>269</b>	<b>275</b>	<b>174</b>	<b>132</b>	<b>84</b>	<b>85</b>	<b>72</b>	<b>74</b>	<b>91</b>	<b>102</b>		
P4B	Cervical cytology - major abnormality	Male (all)	-	-	-	-	-	-	-	-	-	-	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	46	51	38	24	8	12	10	6	15	9	
	<b>Total</b>	<b>46</b>	<b>51</b>	<b>38</b>	<b>24</b>	<b>8</b>	<b>12</b>	<b>10</b>	<b>6</b>	<b>15</b>	<b>9</b>		

Wales: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
S1*	Sexual health screen (no HIV antibody test)	Male (all)	-	-	-	-	-	-	6,172	7,030	7,018	6,655
		-of which MSM	-	-	-	-	-	-	189	159	143	149
		Female	-	-	-	-	-	-	6,091	6,877	7,088	6,611
		<b>Total</b>	-	-	-	-	-	-	<b>12,263</b>	<b>13,907</b>	<b>14,106</b>	<b>13,266</b>
S2*	HIV antibody test and sexual health screen	Male (all)	-	-	-	-	-	-	3,041	4,153	5,839	6,398
		-of which MSM	-	-	-	-	-	-	326	410	538	539
		Female	-	-	-	-	-	-	2,929	3,760	5,222	5,876
		<b>Total</b>	-	-	-	-	-	-	<b>5,970</b>	<b>7,913</b>	<b>11,061</b>	<b>12,274</b>
<b>Total new STI diagnoses</b>	Male (all)	4,012	3,948	4,574	5,188	5,453	5,604	6,151	6,913	7,437	7,017	
	-of which MSM	95	91	120	240	285	306	337	373	369	330	
	Female	3,175	3,393	3,757	4,203	4,363	4,361	4,773	5,075	5,542	5,643	
	<b>Total</b>	<b>7,187</b>	<b>7,341</b>	<b>8,331</b>	<b>9,391</b>	<b>9,816</b>	<b>9,965</b>	<b>10,924</b>	<b>11,988</b>	<b>12,979</b>	<b>12,660</b>	
<b>Total other STI diagnoses</b>	Male (all)	2,207	2,537	2,897	3,015	3,242	3,305	2,905	3,443	3,700	3,966	
	-of which MSM	52	43	62	93	133	129	114	154	158	117	
	Female	1,658	1,939	2,272	2,529	2,406	2,547	2,326	2,718	2,747	2,964	
	<b>Total</b>	<b>3,865</b>	<b>4,476</b>	<b>5,169</b>	<b>5,544</b>	<b>5,648</b>	<b>5,852</b>	<b>5,231</b>	<b>6,161</b>	<b>6,447</b>	<b>6,930</b>	
<b>Total other GUM clinic diagnoses</b>	Male (all)	1,848	1,846	1,917	1,901	2,005	2,017	2,203	2,465	2,795	2,703	
	-of which MSM	4	4	0	5	3	10	2	6	3	3	
	Female	4,906	4,874	4,772	4,950	4,878	5,349	5,638	6,470	7,237	7,415	
	<b>Total</b>	<b>6,754</b>	<b>6,720</b>	<b>6,689</b>	<b>6,851</b>	<b>6,883</b>	<b>7,366</b>	<b>7,841</b>	<b>8,935</b>	<b>10,032</b>	<b>10,118</b>	
<b>Total services provided</b>	Male (all)	4,953	4,975	4,954	5,226	6,629	10,114	17,807	21,414	24,478	25,088	
	-of which MSM	265	263	374	421	550	905	1,069	1,055	1,139	1,144	
	Female	4,256	4,378	4,338	4,804	5,672	8,940	16,286	19,708	22,318	22,685	
	<b>Total</b>	<b>9,209</b>	<b>9,353</b>	<b>9,292</b>	<b>10,030</b>	<b>12,301</b>	<b>19,054</b>	<b>34,093</b>	<b>41,122</b>	<b>46,796</b>	<b>47,773</b>	

Source: HPA Centre for Infections

\* KC60 codes were created/revised in quarter 3, 2002

† previous diagnosis of C11a or C11b treated for more than 3 months

- data not available/applicable



Northern Ireland:

Number of new episodes seen at genitourinary medicine clinics by sex, 1997 - 2006

KC60 codes and conditions			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
A1,A2	Primary and secondary infectious syphilis	Male (all)	1	0	1	0	9	20	10	31	29	27
		-of which MSM	0	0	0	0	8	9	5	21	19	14
		Female	0	0	0	0	2	0	0	10	5	3
		<b>Total</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>11</b>	<b>20</b>	<b>10</b>	<b>41</b>	<b>34</b>	<b>30</b>
A3	Early latent syphilis (first 2 years)	Male (all)	0	2	1	1	1	1	4	1	8	13
		-of which MSM	0	0	0	1	1	1	4	1	6	5
		Female	0	0	0	0	1	1	1	2	6	9
		<b>Total</b>	<b>0</b>	<b>2</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>2</b>	<b>5</b>	<b>3</b>	<b>14</b>	<b>22</b>
A4,A5,A6	Other acquired syphilis	Male (all)	5	3	3	4	2	2	4	5	20	11
		-of which MSM	0	0	0	2	0	0	1	1	2	3
		Female	0	1	4	0	1	1	4	8	17	16
		<b>Total</b>	<b>5</b>	<b>4</b>	<b>7</b>	<b>4</b>	<b>3</b>	<b>3</b>	<b>8</b>	<b>13</b>	<b>37</b>	<b>27</b>
A7	Congenital syphilis, aged under 2	Male (all)	0	0	0	0	0	0	0	0	0	0
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	0	0	0	0	0	0	0	0	0	0
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
A8	Congenital syphilis, aged 2 or over	Male (all)	0	0	0	0	1	0	0	1	0	0
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	0	0	0	0	0	0	0	1	1	0
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>1</b>	<b>0</b>
A9	Epidemiological treatment of suspected syphilis	Male (all)	0	1	6	1	3	3	1	7	1	1
		-of which MSM	0	0	0	0	2	2	0	2	0	1
		Female	0	0	0	0	0	0	1	1	0	2
		<b>Total</b>	<b>0</b>	<b>1</b>	<b>6</b>	<b>1</b>	<b>3</b>	<b>3</b>	<b>2</b>	<b>8</b>	<b>1</b>	<b>3</b>
B1,B2	Uncomplicated gonorrhoea	Male (all)	37	52	91	119	127	106	127	105	162	163
		-of which MSM	1	6	6	11	23	12	39	24	64	39
		Female	12	9	19	24	21	11	27	19	20	32
		<b>Total</b>	<b>49</b>	<b>61</b>	<b>110</b>	<b>143</b>	<b>148</b>	<b>117</b>	<b>154</b>	<b>124</b>	<b>182</b>	<b>195</b>
B3	Gonococcal ophthalmia neonatorum	Male (all)	0	0	0	0	0	0	2	0	2	1
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	0	0	0	0	0	1	1	1	0	1
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>3</b>	<b>1</b>	<b>2</b>	<b>2</b>
B4	Epidemiological treatment of suspected gonorrhoea	Male (all)	3	9	11	14	19	13	15	12	38	26
		-of which MSM	0	1	1	2	8	5	8	2	15	3
		Female	9	13	23	19	29	20	18	20	53	66
		<b>Total</b>	<b>12</b>	<b>22</b>	<b>34</b>	<b>33</b>	<b>48</b>	<b>33</b>	<b>33</b>	<b>32</b>	<b>91</b>	<b>92</b>
B5	Gonococcal complications	Male (all)	2	0	0	3	2	2	3	0	0	1
		-of which MSM	0	0	0	0	0	1	1	0	0	1
		Female	1	1	3	2	0	1	0	2	2	2
		<b>Total</b>	<b>3</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>2</b>	<b>3</b>	<b>3</b>	<b>2</b>	<b>2</b>	<b>3</b>

Northern Ireland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
C1,C2,C3	Chancroid/LGV/Donovanosis	Male (all)	0	1	0	0	0	1	1	1	0	1
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	0	0	0	0	0	0	3	17	7	11
		<b>Total</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>4</b>	<b>18</b>	<b>7</b>	<b>12</b>
C4A,C4C	Uncomplicated chlamydial infection	Male (all)	279	356	416	480	473	548	645	703	783	993
		-of which MSM	1	4	6	8	13	10	27	30	52	63
		Female	275	304	378	483	474	622	663	750	848	986
		<b>Total</b>	<b>554</b>	<b>660</b>	<b>794</b>	<b>963</b>	<b>947</b>	<b>1,170</b>	<b>1,308</b>	<b>1,453</b>	<b>1,631</b>	<b>1,979</b>
C4B	Complicated chlamydial infection	Male (all)	7	12	10	6	10	12	9	9	20	14
		-of which MSM	0	0	0	0	1	1	0	0	0	0
		Female	48	23	27	34	32	28	26	57	62	60
		<b>Total</b>	<b>55</b>	<b>35</b>	<b>37</b>	<b>40</b>	<b>42</b>	<b>40</b>	<b>35</b>	<b>66</b>	<b>82</b>	<b>74</b>
C4D	Chlamydial ophthalmia neonatorum	Male (all)	0	0	1	1	0	2	4	7	5	3
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	3	2	1	2	1	1	1	7	0	4
		<b>Total</b>	<b>3</b>	<b>2</b>	<b>2</b>	<b>3</b>	<b>1</b>	<b>3</b>	<b>5</b>	<b>14</b>	<b>5</b>	<b>7</b>
C4E	Epidemiological treatment of suspected chlamydial infection	Male (all)	36	68	89	128	163	165	220	243	356	344
		-of which MSM	0	2	1	3	3	6	5	7	7	3
		Female	61	69	99	163	147	174	248	284	321	282
		<b>Total</b>	<b>97</b>	<b>137</b>	<b>188</b>	<b>291</b>	<b>310</b>	<b>339</b>	<b>468</b>	<b>527</b>	<b>677</b>	<b>626</b>
C4H*	Uncomplicated non-gonococcal/non-spec urethritis males(females) treatment of mucopurulent cervicitis	Male (all)	1,102	1,558	1,719	1,891	1,674	1,731	1,692	2,074	1,898	1,741
		-of which MSM	20	43	55	66	79	112	73	106	114	79
		Female	0	0	0	0	0	0	148	95	138	115
		<b>Total</b>	<b>1,102</b>	<b>1,558</b>	<b>1,719</b>	<b>1,891</b>	<b>1,674</b>	<b>1,731</b>	<b>1,840</b>	<b>2,169</b>	<b>2,036</b>	<b>1,856</b>
C4I	Epidemiological treatment of NSGI	Male (all)	54	41	34	51	122	56	46	53	68	58
		-of which MSM	0	4	1	2	5	10	3	5	6	8
		Female	347	484	516	637	591	624	497	718	640	493
		<b>Total</b>	<b>401</b>	<b>525</b>	<b>550</b>	<b>688</b>	<b>713</b>	<b>680</b>	<b>543</b>	<b>771</b>	<b>708</b>	<b>551</b>
C5	Complicated infection non-gonococcal/non-chlamydial	Male (all)	72	71	87	79	80	71	65	46	63	49
		-of which MSM	1	0	2	2	2	8	4	2	2	1
		Female	53	67	97	97	89	144	91	121	146	117
		<b>Total</b>	<b>125</b>	<b>138</b>	<b>184</b>	<b>176</b>	<b>169</b>	<b>215</b>	<b>156</b>	<b>167</b>	<b>209</b>	<b>166</b>
C6A	Trichomoniasis	Male (all)	3	4	8	1	2	5	3	3	4	5
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	21	30	32	25	25	35	22	36	31	30
		<b>Total</b>	<b>24</b>	<b>34</b>	<b>40</b>	<b>26</b>	<b>27</b>	<b>40</b>	<b>25</b>	<b>39</b>	<b>35</b>	<b>35</b>
C6B	Anaerobic/bacterial vaginosis & anaerobic balanitis	Male (all)	83	89	94	114	118	64	45	52	50	81
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	652	735	765	852	998	1,128	1,176	1,112	1,323	965
		<b>Total</b>	<b>735</b>	<b>824</b>	<b>859</b>	<b>966</b>	<b>1,116</b>	<b>1,192</b>	<b>1,221</b>	<b>1,164</b>	<b>1,373</b>	<b>1,046</b>
C6C	Other vaginosis/vaginitis/balanitis	Male (all)	22	90	92	100	181	257	148	104	170	149
		-of which MSM	-	-	-	-	-	-	-	-	-	-
		Female	37	42	34	54	72	75	121	108	111	88
		<b>Total</b>	<b>59</b>	<b>132</b>	<b>126</b>	<b>154</b>	<b>253</b>	<b>332</b>	<b>269</b>	<b>212</b>	<b>281</b>	<b>237</b>

Northern Ireland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	
C7A	Genital candidosis	Male (all)	660	692	617	615	693	686	567	388	458	456	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	1,031	907	805	975	1,082	1,123	897	698	868	632	
		<b>Total</b>	<b>1,691</b>	<b>1,599</b>	<b>1,422</b>	<b>1,590</b>	<b>1,775</b>	<b>1,809</b>	<b>1,464</b>	<b>1,086</b>	<b>1,326</b>	<b>1,088</b>	
C7B	Epidemiological treatment of C6 & C7	Male (all)	31	15	9	4	8	16	7	23	4	7	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	9	10	3	9	5	9	10	27	12	13	
		<b>Total</b>	<b>40</b>	<b>25</b>	<b>12</b>	<b>13</b>	<b>13</b>	<b>25</b>	<b>17</b>	<b>50</b>	<b>16</b>	<b>20</b>	
C8,C9	Scabies/pediculosis pubis	Male (all)	152	174	145	147	118	170	106	69	47	55	
		-of which MSM	2	9	10	13	14	25	17	9	4	15	
		Female	63	45	45	62	47	52	34	21	8	7	
		<b>Total</b>	<b>215</b>	<b>219</b>	<b>190</b>	<b>209</b>	<b>165</b>	<b>222</b>	<b>140</b>	<b>90</b>	<b>55</b>	<b>62</b>	
C10A	Genital herpes simplex – first attack	Male (all)	73	61	73	108	93	79	60	69	66	91	
		-of which MSM	1	2	1	3	3	1	3	5	5	2	
		Female	117	115	111	173	165	180	166	153	172	183	
		<b>Total</b>	<b>190</b>	<b>176</b>	<b>184</b>	<b>281</b>	<b>258</b>	<b>259</b>	<b>226</b>	<b>222</b>	<b>238</b>	<b>274</b>	
C10B	Genital herpes simplex – recurrence	Male (all)	37	49	59	64	81	60	48	33	49	59	
		-of which MSM	0	2	0	2	4	6	1	3	4	1	
		Female	56	60	69	66	95	78	85	73	79	85	
		<b>Total</b>	<b>93</b>	<b>109</b>	<b>128</b>	<b>130</b>	<b>176</b>	<b>138</b>	<b>133</b>	<b>106</b>	<b>128</b>	<b>144</b>	
C11A	Genital warts – first attack	Male (all)	848	1,295	1,138	1,118	1,107	1,147	1,111	1,059	1,208	1,142	
		-of which MSM	12	21	13	22	28	28	23	36	40	22	
		Female	853	831	892	999	1,023	1,029	1,065	1,042	1,098	1,014	
		<b>Total</b>	<b>1,701</b>	<b>2,126</b>	<b>2,030</b>	<b>2,117</b>	<b>2,130</b>	<b>2,176</b>	<b>2,176</b>	<b>2,101</b>	<b>2,306</b>	<b>2,156</b>	
C11B	Genital warts – recurrence	Male (all)	345	1,188	817	635	460	462	407	320	465	443	
		-of which MSM	1	17	22	18	10	12	12	9	13	7	
		Female	230	214	180	185	204	198	256	233	360	342	
		<b>Total</b>	<b>575</b>	<b>1,402</b>	<b>997</b>	<b>820</b>	<b>664</b>	<b>660</b>	<b>663</b>	<b>553</b>	<b>825</b>	<b>785</b>	
C11C	Genital warts – re-registered cases†	Male (all)	2	52	52	67	107	121	75	83	52	94	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	0	31	22	26	30	45	35	66	54	65	
		<b>Total</b>	<b>2</b>	<b>83</b>	<b>74</b>	<b>93</b>	<b>137</b>	<b>166</b>	<b>110</b>	<b>149</b>	<b>106</b>	<b>159</b>	
C12	Molluscum contagiosum	Male (all)	3	43	48	75	83	90	94	84	117	148	
		-of which MSM	0	0	1	1	5	5	3	2	3	3	
		Female	2	23	37	52	36	47	48	48	61	65	
		<b>Total</b>	<b>5</b>	<b>66</b>	<b>85</b>	<b>127</b>	<b>119</b>	<b>137</b>	<b>142</b>	<b>132</b>	<b>178</b>	<b>213</b>	
C13	Antigen positive viral hepatitis B	Male (all)	2	1	2	3	3	3	1	0	0	0	
		-of which MSM	0	0	0	0	1	0	0	0	0	0	
		Female	0	0	1	1	1	1	0	0	0	0	
		<b>Total</b>	<b>2</b>	<b>1</b>	<b>3</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	
C13A*	Viral hepatitis B (HbsAg positive): first diagnosis**	Male (all)	-	-	-	-	-	-	5	6	3	7	
		-of which MSM	-	-	-	-	-	-	1	1	0	1	
		Female	-	-	-	-	-	-	0	1	0	2	
		<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>5</b>	<b>7</b>	<b>3</b>	<b>9</b>	

Northern Ireland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	
C13B*	**number of which were acute viral hepatitis B	Male (all)	-	-	-	-	-	-	0	1	2	2	
		-of which MSM	-	-	-	-	-	-	0	0	0	0	
		Female	-	-	-	-	-	-	0	0	1	0	
		<b>Total</b>	-	-	-	-	-	-	<b>0</b>	<b>1</b>	<b>3</b>	<b>2</b>	
C13C*	Viral hepatitis B: subsequent presentation	Male (all)	-	-	-	-	-	-	3	1	2	4	
		-of which MSM	-	-	-	-	-	-	0	0	0	1	
		Female	-	-	-	-	-	-	0	0	0	0	
		<b>Total</b>	-	-	-	-	-	-	<b>3</b>	<b>1</b>	<b>2</b>	<b>4</b>	
C14*	Viral hepatitis C: fist diagnosis (previous to 2003 C14 was other viral hepatitis)	Male (all)	0	3	2	4	3	1	4	1	4	8	
		-of which MSM	0	0	0	0	0	0	0	0	0	1	0
		Female	0	0	4	0	0	1	0	0	0	2	3
		<b>Total</b>	0	3	6	4	3	2	<b>4</b>	<b>1</b>	<b>6</b>	<b>11</b>	
E1A	Asymptomatic HIV infection – first presentation	Male (all)	10	8	5	5	8	9	15	12	15	30	
		-of which MSM	0	2	2	2	2	2	2	6	6	14	
		Female	5	5	2	6	5	3	2	6	14	13	
		<b>Total</b>	<b>15</b>	<b>13</b>	<b>7</b>	<b>11</b>	<b>13</b>	<b>12</b>	<b>17</b>	<b>18</b>	<b>29</b>	<b>43</b>	
E1B*	Asymptomatic HIV infection – subsequent presentation	Male (all)	103	94	98	99	86	90	43	0	0	0	
		-of which MSM	0	0	0	0	0	0	0	0	0	0	
		Female	17	33	10	25	13	14	6	0	0	0	
		<b>Total</b>	<b>120</b>	<b>127</b>	<b>108</b>	<b>124</b>	<b>99</b>	<b>104</b>	<b>49</b>	<b>0</b>	<b>0</b>	<b>0</b>	
E1BE2B*	Subsequent HIV presentation (not AIDS)	Male (all)	-	-	-	-	-	-	139	90	122	53	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	-	-	-	-	-	-	-	46	31	66	10
		<b>Total</b>	-	-	-	-	-	-	<b>185</b>	<b>121</b>	<b>188</b>	<b>63</b>	
E2A	HIV infection with symptoms, not AIDS – first presentation	Male (all)	26	8	7	11	5	2	6	6	5	6	
		-of which MSM	9	5	2	4	4	1	2	2	3	2	
		Female	2	1	1	2	3	0	1	6	4	1	
		<b>Total</b>	<b>28</b>	<b>9</b>	<b>8</b>	<b>13</b>	<b>8</b>	<b>2</b>	<b>7</b>	<b>12</b>	<b>9</b>	<b>7</b>	
E2B*	HIV infection with symptoms, not AIDS – subsequent presentation	Male (all)	0	56	55	72	68	54	4	0	0	0	
		-of which MSM	0	0	0	0	0	0	0	0	0	0	
		Female	4	16	15	20	12	10	0	0	0	0	
		<b>Total</b>	<b>4</b>	<b>72</b>	<b>70</b>	<b>92</b>	<b>80</b>	<b>64</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>0</b>	
E3A*	AIDS – first presentation	Male (all)	14	7	5	8	2	9	2	0	0	0	
		-of which MSM	7	2	2	4	1	7	0	0	0	0	
		Female	0	0	0	0	2	1	0	0	0	0	
		<b>Total</b>	<b>14</b>	<b>7</b>	<b>5</b>	<b>8</b>	<b>4</b>	<b>10</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	
E3A1*	AIDS: first presentation - new HIV diagnosis	Male (all)	-	-	-	-	-	-	2	0	2	1	
		-of which MSM	-	-	-	-	-	-	2	0	1	0	
		Female	-	-	-	-	-	-	1	2	0	1	
		<b>Total</b>	-	-	-	-	-	-	<b>3</b>	<b>2</b>	<b>2</b>	<b>2</b>	
E3A2*	AIDS: first presentation - HIV diagnosed previously	Male (all)	-	-	-	-	-	-	4	3	1	3	
		-of which MSM	-	-	-	-	-	-	3	2	1	0	
		Female	-	-	-	-	-	-	0	0	0	0	
		<b>Total</b>	-	-	-	-	-	-	<b>4</b>	<b>3</b>	<b>1</b>	<b>3</b>	

Northern Ireland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	
E3B	AIDS – subsequent presentation	Male (all)	15	146	138	113	136	128	76	18	17	2	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	9	41	46	38	46	25	27	8	1	0	
		<b>Total</b>	<b>24</b>	<b>187</b>	<b>184</b>	<b>151</b>	<b>182</b>	<b>153</b>	<b>103</b>	<b>26</b>	<b>18</b>	<b>2</b>	
D2A	Urinary tract infection	Male (all)	0	31	33	43	58	43	50	29	27	38	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	4	57	67	95	71	84	39	36	41	39	
		<b>Total</b>	<b>4</b>	<b>88</b>	<b>100</b>	<b>138</b>	<b>129</b>	<b>127</b>	<b>89</b>	<b>65</b>	<b>68</b>	<b>77</b>	
D2B	Other conditions requiring treatment at GUM clinic	Male (all)	2,575	1,148	552	700	726	786	429	305	370	384	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	3,118	1,146	353	492	452	494	261	246	241	225	
		<b>Total</b>	<b>5,693</b>	<b>2,294</b>	<b>905</b>	<b>1,192</b>	<b>1,178</b>	<b>1,280</b>	<b>690</b>	<b>551</b>	<b>611</b>	<b>609</b>	
D3	Other episodes not requiring treatment	Male (all)	1,787	1,787	1,908	1,932	2,430	2,959	1,685	1,146	1,327	1,148	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	-
		Female	1,690	1,518	1,417	1,513	1,987	2,210	1,370	1,073	930	898	
		<b>Total</b>	<b>3,477</b>	<b>3,305</b>	<b>3,325</b>	<b>3,445</b>	<b>4,417</b>	<b>5,169</b>	<b>3,055</b>	<b>2,219</b>	<b>2,257</b>	<b>2,046</b>	
P1A	HIV antibody counselling - with testing	Male (all)	74	484	523	650	718	893	432	180	151	177	
		-of which MSM	0	51	41	65	107	147	77	18	19	17	
		Female	50	339	351	397	549	545	251	119	124	126	
		<b>Total</b>	<b>124</b>	<b>823</b>	<b>874</b>	<b>1,047</b>	<b>1,267</b>	<b>1,438</b>	<b>683</b>	<b>299</b>	<b>275</b>	<b>303</b>	
P1B	HIV antibody counselling - without testing	Male (all)	7	100	113	162	230	152	58	77	226	196	
		-of which MSM	0	14	10	25	43	24	14	3	9	8	
		Female	2	75	77	94	100	81	85	42	46	87	
		<b>Total</b>	<b>9</b>	<b>175</b>	<b>190</b>	<b>256</b>	<b>330</b>	<b>233</b>	<b>143</b>	<b>119</b>	<b>272</b>	<b>283</b>	
P2	Hepatitis B vaccination	Male (all)	3	129	137	171	273	295	191	161	215	220	
		-of which MSM	0	38	31	61	125	140	97	73	110	80	
		Female	0	18	13	20	41	19	23	16	29	37	
		<b>Total</b>	<b>3</b>	<b>147</b>	<b>150</b>	<b>191</b>	<b>314</b>	<b>314</b>	<b>214</b>	<b>177</b>	<b>244</b>	<b>257</b>	
P3	Family Planning	Male (all)	-	-	-	-	-	-	-	-	-	-	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	7	97	93	96	152	81	33	36	24	18	
		<b>Total</b>	<b>7</b>	<b>97</b>	<b>93</b>	<b>96</b>	<b>152</b>	<b>81</b>	<b>33</b>	<b>36</b>	<b>24</b>	<b>18</b>	
P4A	Cervical cytology - minor abnormality	Male (all)	-	-	-	-	-	-	-	-	-	-	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	11	374	303	163	98	100	71	25	4	5	
		<b>Total</b>	<b>11</b>	<b>374</b>	<b>303</b>	<b>163</b>	<b>98</b>	<b>100</b>	<b>71</b>	<b>25</b>	<b>4</b>	<b>5</b>	
P4B	Cervical cytology - major abnormality	Male (all)	-	-	-	-	-	-	-	-	-	-	
		-of which MSM	-	-	-	-	-	-	-	-	-	-	
		Female	5	15	9	2	1	2	1	14	0	2	
		<b>Total</b>	<b>5</b>	<b>15</b>	<b>9</b>	<b>2</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>14</b>	<b>0</b>	<b>2</b>	

Northern Ireland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
S1*	Sexual health screen (no HIV antibody test)	Male (all)	-	-	-	-	-	-	3,210	3,459	2,412	908
		-of which MSM	-	-	-	-	-	-	77	91	60	35
		Female	-	-	-	-	-	-	3,135	3,597	2,739	957
		<b>Total</b>	-	-	-	-	-	-	<b>6,345</b>	<b>7,056</b>	<b>5,151</b>	<b>1,865</b>
S2*	HIV antibody test and sexual health screen	Male (all)	-	-	-	-	-	-	1,133	1,970	4,574	5,667
		-of which MSM	-	-	-	-	-	-	101	175	298	260
		Female	-	-	-	-	-	-	752	1,852	3,364	4,710
		<b>Total</b>	-	-	-	-	-	-	<b>1,885</b>	<b>3,822</b>	<b>7,938</b>	<b>10,377</b>
<b>Total new STI diagnoses</b>			2,615	3,643	3,748	4,043	3,791	3,993	3,949	4,271	4,419	4,467
	-of which MSM	47	92	98	132	182	215	201	243	313	255	
	Female	1,452	1,454	1,644	1,959	1,922	2,152	2,297	2,385	2,616	2,640	
	<b>Total</b>	<b>4,067</b>	<b>5,097</b>	<b>5,392</b>	<b>6,002</b>	<b>5,713</b>	<b>6,145</b>	<b>6,246</b>	<b>6,656</b>	<b>7,035</b>	<b>7,107</b>	
<b>Total other STI diagnoses</b>			614	1,716	1,369	1,258	1,251	1,166	1,094	876	1,204	1,111
	-of which MSM	8	28	27	34	34	49	37	32	54	31	
	Female	736	964	985	1,181	1,172	1,193	1,226	1,453	1,598	1,375	
	<b>Total</b>	<b>1,350</b>	<b>2,680</b>	<b>2,354</b>	<b>2,439</b>	<b>2,423</b>	<b>2,359</b>	<b>2,320</b>	<b>2,329</b>	<b>2,802</b>	<b>2,486</b>	
<b>Total other GUM clinic diagnoses</b>			3,373	2,069	1,401	1,583	1,790	1,856	1,259	910	1,090	1,136
	-of which MSM	0	0	0	0	1	0	1	1	1	2	
	Female	4,867	3,286	2,344	2,643	2,780	3,017	2,576	2,267	2,603	1,974	
	<b>Total</b>	<b>8,240</b>	<b>5,355</b>	<b>3,745</b>	<b>4,226</b>	<b>4,570</b>	<b>4,873</b>	<b>3,835</b>	<b>3,177</b>	<b>3,693</b>	<b>3,110</b>	
<b>Total services provided</b>			1,871	2,500	2,681	2,915	3,651	4,299	6,709	6,993	8,905	8,316
	-of which MSM	0	103	82	151	275	311	366	360	496	400	
	Female	1,749	2,047	1,951	2,120	2,829	2,936	5,649	6,735	7,256	6,833	
	<b>Total</b>	<b>3,620</b>	<b>4,547</b>	<b>4,632</b>	<b>5,035</b>	<b>6,480</b>	<b>7,235</b>	<b>12,358</b>	<b>13,728</b>	<b>16,161</b>	<b>15,149</b>	

Source: HPA Centre for Infections

\* KC60 codes were created/revised in quarter 3, 2002

† previous diagnosis of C11a or C11b treated for more than 3 months

- data not available/applicable



Scotland:

Number of new episodes seen at genitourinary medicine clinics by sex, 1997 - 2006

ISD codes and conditions			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
A1	Primary Syphilis	Male (all)	4	1	3	7	4	17	31	111	99	110
		-of which MSM	0	0	1	4	2	13	24	89	86	96
		Female	4	5	2	2	7	1	1	5	5	4
		<b>Total</b>	<b>8</b>	<b>6</b>	<b>5</b>	<b>9</b>	<b>11</b>	<b>18</b>	<b>32</b>	<b>116</b>	<b>104</b>	<b>114</b>
A2	Secondary Syphilis	Male (all)	2	1	3	5	5	10	18	47	49	73
		-of which MSM	0	0	0	3	1	8	9	28	44	61
		Female	1	0	0	1	1	1	4	1	0	0
		<b>Total</b>	<b>3</b>	<b>1</b>	<b>3</b>	<b>6</b>	<b>6</b>	<b>11</b>	<b>22</b>	<b>48</b>	<b>49</b>	<b>73</b>
A3	Early Latent Syphilis (first 2 years of infection)	Male (all)	3	1	2	7	3	17	18	25	30	51
		-of which MSM	1	1	1	2	3	11	10	18	24	42
		Female	1	0	2	0	4	5	3	0	5	8
		<b>Total</b>	<b>4</b>	<b>1</b>	<b>4</b>	<b>7</b>	<b>7</b>	<b>22</b>	<b>21</b>	<b>25</b>	<b>35</b>	<b>59</b>
A4	Cardiovascular Syphilis	Male (all)	0	0	0	1	1	0	0	0	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	0	0	0	0	0	0	0	0	0	0
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
A5	Neurosyphilis	Male (all)	1	0	0	0	0	0	1	0	3	2
		-of which MSM	0	0	0	0	0	0	0	0	2	0
		Female	0	1	1	0	0	0	0	0	0	1
		<b>Total</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>3</b>	<b>3</b>
A6	All other late and latent Syphilis	Male (all)	12	14	8	11	16	19	16	18	34	26
		-of which MSM	4	3	2	4	6	5	5	7	17	8
		Female	7	4	7	2	7	18	15	14	10	10
		<b>Total</b>	<b>19</b>	<b>18</b>	<b>15</b>	<b>13</b>	<b>23</b>	<b>37</b>	<b>31</b>	<b>32</b>	<b>44</b>	<b>36</b>
A7	Congenital Syphilis (age <2 years)	Male (all)	0	0	0	1	0	0	0	0	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	1	0	0	0	0	0	0	0	0	0
		<b>Total</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
A8	Congenital Syphilis (age >2 years)	Male (all)	0	0	0	0	0	0	0	0	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	1	1	2	0	0	0	1	0	0	1
		<b>Total</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1</b>
A9	Epidemiological treatment of suspected Syphilis	Male (all)	0	0	1	0	0	6	13	44	43	36
		-of which MSM	0	0	0	0	0	3	12	38	40	32
		Female	0	0	1	0	0	1	2	4	4	4
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>7</b>	<b>15</b>	<b>48</b>	<b>47</b>	<b>40</b>
A10	Previously treated Syphilis	Male (all)	14	30	47	39	48	46	99	205	384	439
		-of which MSM	6	13	31	22	32	33	74	160	339	377
		Female	3	4	1	10	5	15	18	31	26	33
		<b>Total</b>	<b>17</b>	<b>34</b>	<b>48</b>	<b>49</b>	<b>53</b>	<b>61</b>	<b>117</b>	<b>236</b>	<b>410</b>	<b>472</b>

Scotland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
A11	Non-treponemal reactive syphilis serology	Male (all)	1	6	2	4	4	8	1	0	4	0
		-of which MSM	0	0	0	0	0	2	0	0	2	0
		Female	3	6	1	2	3	1	4	2	1	1
		<b>Total</b>	<b>4</b>	<b>12</b>	<b>3</b>	<b>6</b>	<b>7</b>	<b>9</b>	<b>5</b>	<b>2</b>	<b>5</b>	<b>1</b>
B11	Gonorrhoea, Lower genital tract infection	Male (all)	266	234	303	455	470	425	477	499	533	516
		-of which MSM	91	59	74	143	127	160	191	170	206	197
		Female	71	91	118	146	162	149	105	125	162	150
		<b>Total</b>	<b>337</b>	<b>325</b>	<b>421</b>	<b>601</b>	<b>632</b>	<b>574</b>	<b>582</b>	<b>624</b>	<b>695</b>	<b>666</b>
B12	Gonorrhoea, mouth and throat infection	Male (all)	29	20	21	31	27	29	40	35	39	75
		-of which MSM	26	17	16	27	23	25	33	29	34	64
		Female	1	2	9	4	5	2	7	10	8	14
		<b>Total</b>	<b>30</b>	<b>22</b>	<b>30</b>	<b>35</b>	<b>32</b>	<b>31</b>	<b>47</b>	<b>45</b>	<b>47</b>	<b>89</b>
B13	Gonorrhoea, eye infection	Male (all)	0	0	0	0	0	1	1	1	0	2
		-of which MSM	0	0	0	0	0	1	1	0	0	2
		Female	0	0	0	0	0	0	0	0	0	1
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>3</b>
B14	Gonorrhoea, rectal infection	Male (all)	36	27	35	41	48	67	92	71	77	124
		-of which MSM	33	25	33	40	40	64	86	61	73	116
		Female	4	9	8	11	16	8	12	12	11	5
		<b>Total</b>	<b>40</b>	<b>36</b>	<b>43</b>	<b>52</b>	<b>64</b>	<b>75</b>	<b>104</b>	<b>83</b>	<b>88</b>	<b>129</b>
B15	Gonorrhoea, upper genital tract complications	Male (all)	0	1	3	2	1	1	4	0	0	4
		-of which MSM	0	1	1	1	0	0	2	0	0	2
		Female	1	5	4	5	10	5	5	7	4	5
		<b>Total</b>	<b>1</b>	<b>6</b>	<b>7</b>	<b>7</b>	<b>11</b>	<b>6</b>	<b>9</b>	<b>7</b>	<b>4</b>	<b>9</b>
B16	Gonorrhoea, systemic complications	Male (all)	1	0	0	0	0	2	0	0	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	0	0	0	0	0	1	0	0	0	0
		<b>Total</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>3</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
B2	Prepubertal gonorrhoea	Male (all)	0	0	3	0	0	0	0	0	0	0
		-of which MSM	0	0	1	0	0	0	0	0	0	0
		Female	0	0	7	2	0	0	0	0	0	0
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>10</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
B3	Gonococcal ophthalmia neonatorum	Male (all)	0	0	0	0	0	0	0	0	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	0	0	0	0	1	0	0	0	0	0
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
B4	Epidemiological treatment of suspected gonorrhoea	Male (all)	39	31	34	85	88	92	116	141	193	211
		-of which MSM	21	15	16	37	26	35	58	66	97	120
		Female	31	17	34	43	53	60	61	89	101	124
		<b>Total</b>	<b>70</b>	<b>48</b>	<b>68</b>	<b>128</b>	<b>141</b>	<b>152</b>	<b>177</b>	<b>230</b>	<b>294</b>	<b>335</b>

Scotland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
C1	Chancroid	Male (all)	0	0	0	1	0	1	1	0	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	0	0	0	0	1	0	1	4	0	1
		<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>4</b>	<b>0</b>	<b>1</b>
C2	Lymphogranuloma venereum	Male (all)	1	2	2	0	0	0	1	1	2	3
		-of which MSM	0	0	0	0	0	0	0	0	1	3
		Female	1	2	1	1	0	0	0	0	0	0
		<b>Total</b>	<b>2</b>	<b>4</b>	<b>3</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>3</b>
C3	Granuloma inguinale	Male (all)	1	0	0	1	1	1	1	0	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	1	1	0	1	2	1	0	0	0	1
		<b>Total</b>	<b>2</b>	<b>1</b>	<b>0</b>	<b>2</b>	<b>3</b>	<b>2</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1</b>
C41A	Chlamydial infection - lower genital tract	Male (all)	914	1,158	1,478	1,738	2,150	2,538	3,022	3,451	3,855	4,071
		-of which MSM	28	34	39	71	81	109	161	192	165	174
		Female	1,154	1,396	1,743	1,834	2,415	2,780	3,010	3,222	3,828	4,255
		<b>Total</b>	<b>2,068</b>	<b>2,554</b>	<b>3,221</b>	<b>3,572</b>	<b>4,565</b>	<b>5,318</b>	<b>6,032</b>	<b>6,673</b>	<b>7,683</b>	<b>8,326</b>
C41B	Chlamydial infection - upper genital tract	Male (all)	9	14	16	23	33	31	23	39	42	31
		-of which MSM	0	0	1	2	4	1	2	3	2	1
		Female	44	77	97	96	192	203	213	145	135	154
		<b>Total</b>	<b>53</b>	<b>91</b>	<b>113</b>	<b>119</b>	<b>225</b>	<b>234</b>	<b>236</b>	<b>184</b>	<b>177</b>	<b>185</b>
C41C	Chlamydial infection - other sites	Male (all)	11	10	27	33	53	80	169	57	3	5
		-of which MSM	2	4	18	21	38	72	156	46	1	2
		Female	6	7	4	4	6	8	13	11	3	2
		<b>Total</b>	<b>17</b>	<b>17</b>	<b>31</b>	<b>37</b>	<b>59</b>	<b>88</b>	<b>182</b>	<b>68</b>	<b>6</b>	<b>7</b>
C41D	Epidemiological treatment of suspected Chlamydial infection	Male (all)	474	593	739	836	1,170	1,376	1,585	1,789	1,920	2,206
		-of which MSM	4	6	10	21	37	70	160	175	215	246
		Female	231	299	370	419	624	742	886	1,028	1,176	1,292
		<b>Total</b>	<b>705</b>	<b>892</b>	<b>1,109</b>	<b>1,255</b>	<b>1,794</b>	<b>2,118</b>	<b>2,471</b>	<b>2,817</b>	<b>3,096</b>	<b>3,498</b>
C41E	Chlamydial infection, eye	Male (all)	-	-	-	-	-	-	-	11	14	13
		-of which MSM	-	-	-	-	-	-	-	0	2	1
		Female	-	-	-	-	-	-	-	3	10	9
		<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>14</b>	<b>24</b>	<b>22</b>
C41R	Chlamydial infection, rectal	Male (all)	-	-	-	-	-	-	-	146	198	269
		-of which MSM	-	-	-	-	-	-	-	128	187	252
		Female	-	-	-	-	-	-	-	4	7	23
		<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>150</b>	<b>205</b>	<b>292</b>
C42A	NSGI (Non-Chlamydial) - lower genital tract	Male (all)	1,740	1,525	1,635	1,437	1,638	1,760	1,577	1,648	1,567	1,506
		-of which MSM	102	81	139	118	130	165	125	197	157	145
		Female	181	175	197	160	129	134	112	107	64	57
		<b>Total</b>	<b>1,921</b>	<b>1,700</b>	<b>1,832</b>	<b>1,597</b>	<b>1,767</b>	<b>1,894</b>	<b>1,689</b>	<b>1,755</b>	<b>1,631</b>	<b>1,563</b>

Scotland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
C42B	NSGI (Non-Chlamydial) - upper genital tract	Male (all)	100	96	113	154	131	149	138	127	171	149
		-of which MSM	11	4	5	13	5	7	9	6	18	17
		Female	118	132	163	150	184	218	201	213	208	183
		<b>Total</b>	<b>218</b>	<b>228</b>	<b>276</b>	<b>304</b>	<b>315</b>	<b>367</b>	<b>339</b>	<b>340</b>	<b>379</b>	<b>332</b>
C42C	Non-specific proctitis	Male (all)	3	4	8	11	8	4	5	7	2	14
		-of which MSM	1	2	7	10	7	3	3	7	2	12
		Female	0	1	0	0	0	0	0	0	1	0
		<b>Total</b>	<b>3</b>	<b>5</b>	<b>8</b>	<b>11</b>	<b>8</b>	<b>4</b>	<b>5</b>	<b>7</b>	<b>3</b>	<b>14</b>
C42D	Epidemiological treatment for suspected NSGI	Male (all)	141	120	124	135	162	173	249	148	127	133
		-of which MSM	8	12	10	29	34	40	50	18	20	21
		Female	364	298	260	199	238	260	184	148	161	176
		<b>Total</b>	<b>505</b>	<b>418</b>	<b>384</b>	<b>334</b>	<b>400</b>	<b>433</b>	<b>433</b>	<b>296</b>	<b>288</b>	<b>309</b>
C43	Balanitis	Male (all)	956	986	1,032	972	1,011	1,070	1,063	1,177	1,113	1,124
		-of which MSM	48	53	58	40	59	67	72	61	64	65
		Female	0	0	0	0	0	0	0	0	0	0
		<b>Total</b>	<b>956</b>	<b>986</b>	<b>1,032</b>	<b>972</b>	<b>1,011</b>	<b>1,070</b>	<b>1,063</b>	<b>1,177</b>	<b>1,113</b>	<b>1,124</b>
C44	Prostatitis	Male (all)	35	38	34	33	24	26	29	24	33	25
		-of which MSM	3	2	6	3	2	6	3	1	2	1
		Female	0	0	0	0	0	0	0	0	0	0
		<b>Total</b>	<b>35</b>	<b>38</b>	<b>34</b>	<b>33</b>	<b>24</b>	<b>26</b>	<b>29</b>	<b>24</b>	<b>33</b>	<b>25</b>
C45	Urinary tract infection (Culture + ve)	Male (all)	60	54	41	30	45	43	63	42	36	40
		-of which MSM	9	8	6	3	8	6	2	4	7	8
		Female	116	129	122	106	147	144	171	151	161	170
		<b>Total</b>	<b>176</b>	<b>183</b>	<b>163</b>	<b>136</b>	<b>192</b>	<b>187</b>	<b>234</b>	<b>193</b>	<b>197</b>	<b>210</b>
C5	Seronegative Reactive Arthritis	Male (all)	21	19	17	19	11	17	14	11	16	21
		-of which MSM	0	0	0	0	1	0	0	0	2	1
		Female	1	1	1	1	1	2	1	1	4	0
		<b>Total</b>	<b>22</b>	<b>20</b>	<b>18</b>	<b>20</b>	<b>12</b>	<b>19</b>	<b>15</b>	<b>12</b>	<b>20</b>	<b>21</b>
C6A	Trichomoniasis	Male (all)	12	14	15	14	28	37	28	45	47	48
		-of which MSM	1	0	0	0	0	0	0	0	0	1
		Female	92	93	76	58	93	79	96	82	80	115
		<b>Total</b>	<b>104</b>	<b>107</b>	<b>91</b>	<b>72</b>	<b>121</b>	<b>116</b>	<b>124</b>	<b>127</b>	<b>127</b>	<b>163</b>
C6B	Bacterial vaginosis	Male (all)	0	0	0	0	0	0	0	0	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	1,243	1,340	1,374	1,498	1,711	2,053	2,135	2,320	2,687	2,707
		<b>Total</b>	<b>1,243</b>	<b>1,340</b>	<b>1,374</b>	<b>1,498</b>	<b>1,711</b>	<b>2,053</b>	<b>2,135</b>	<b>2,320</b>	<b>2,687</b>	<b>2,707</b>
C7	Genital candidiasis	Male (all)	192	176	169	210	202	134	170	188	157	251
		-of which MSM	8	8	11	13	13	6	15	19	10	26
		Female	1,546	1,549	1,567	1,612	1,661	1,777	1,866	2,034	1,994	2,074
		<b>Total</b>	<b>1,738</b>	<b>1,725</b>	<b>1,736</b>	<b>1,822</b>	<b>1,863</b>	<b>1,911</b>	<b>2,036</b>	<b>2,222</b>	<b>2,151</b>	<b>2,325</b>

Scotland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
C8	Genital scabies	Male (all)	118	121	124	148	116	127	148	112	104	98
		-of which MSM	32	32	27	46	43	55	60	38	26	32
		Female	18	16	10	10	6	7	7	10	14	6
		<b>Total</b>	<b>136</b>	<b>137</b>	<b>134</b>	<b>158</b>	<b>122</b>	<b>134</b>	<b>155</b>	<b>122</b>	<b>118</b>	<b>104</b>
C9	Pubic lice	Male (all)	172	187	177	164	160	120	143	125	115	107
		-of which MSM	50	51	44	41	51	33	39	36	57	59
		Female	53	55	45	38	37	31	37	21	17	13
		<b>Total</b>	<b>225</b>	<b>242</b>	<b>222</b>	<b>202</b>	<b>197</b>	<b>151</b>	<b>180</b>	<b>146</b>	<b>132</b>	<b>120</b>
C10A1	Genital herpes, first occurrence (laboratory confirmed, type 1)	Male (all)	-	-	-	-	-	-	-	95	161	164
		-of which MSM	-	-	-	-	-	-	-	13	24	35
		Female	-	-	-	-	-	-	-	216	339	368
		<b>Total</b>	-	-	-	-	-	-	-	<b>311</b>	<b>500</b>	<b>532</b>
C10A2	Genital herpes, first occurrence (laboratory confirmed, type 2)	Male (all)	-	-	-	-	-	-	-	157	183	245
		-of which MSM	-	-	-	-	-	-	-	7	15	15
		Female	-	-	-	-	-	-	-	159	231	216
		<b>Total</b>	-	-	-	-	-	-	-	<b>316</b>	<b>414</b>	<b>461</b>
C10AN	Genital herpes, first occurrence (no laboratory confirmation)	Male (all)	154	155	139	140	151	145	142	152	127	154
		-of which MSM	9	9	11	21	19	16	11	23	22	25
		Female	230	202	219	180	202	230	222	207	212	174
		<b>Total</b>	<b>384</b>	<b>357</b>	<b>358</b>	<b>320</b>	<b>353</b>	<b>375</b>	<b>364</b>	<b>359</b>	<b>339</b>	<b>328</b>
C10AP	Genital herpes, first occurrence (laboratory confirmed, non-typed)	Male (all)	184	177	227	214	265	254	350	120	34	25
		-of which MSM	9	17	17	18	16	19	36	10	4	5
		Female	281	293	354	364	472	424	529	177	45	44
		<b>Total</b>	<b>465</b>	<b>470</b>	<b>581</b>	<b>578</b>	<b>737</b>	<b>678</b>	<b>879</b>	<b>297</b>	<b>79</b>	<b>69</b>
C10B1	Genital herpes, recurrence (laboratory confirmed, type 1)	Male (all)	-	-	-	-	-	-	-	6	13	13
		-of which MSM	-	-	-	-	-	-	-	4	1	5
		Female	-	-	-	-	-	-	-	26	36	42
		<b>Total</b>	-	-	-	-	-	-	-	<b>32</b>	<b>49</b>	<b>55</b>
C10B2	Genital herpes, recurrence (laboratory confirmed, type 2)	Male (all)	-	-	-	-	-	-	-	80	70	64
		-of which MSM	-	-	-	-	-	-	-	14	4	6
		Female	-	-	-	-	-	-	-	49	52	64
		<b>Total</b>	-	-	-	-	-	-	-	<b>129</b>	<b>122</b>	<b>128</b>
C10BN	Genital herpes, recurrence (no laboratory confirmation)	Male (all)	191	221	223	278	287	299	272	305	322	340
		-of which MSM	22	17	14	15	21	26	30	41	51	56
		Female	199	236	252	259	284	317	308	306	307	313
		<b>Total</b>	<b>390</b>	<b>457</b>	<b>475</b>	<b>537</b>	<b>571</b>	<b>616</b>	<b>580</b>	<b>611</b>	<b>629</b>	<b>653</b>
C10BP	Genital herpes, recurrence (laboratory confirmed, non typed)	Male (all)	29	51	43	28	51	73	88	38	12	4
		-of which MSM	6	3	6	0	6	7	6	7	0	0
		Female	60	60	67	65	102	85	94	50	24	12
		<b>Total</b>	<b>89</b>	<b>111</b>	<b>110</b>	<b>93</b>	<b>153</b>	<b>158</b>	<b>182</b>	<b>88</b>	<b>36</b>	<b>16</b>

Scotland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
C10CN	Oral labial herpes (no culture confirmation)	Male (all)	13	9	5	13	6	4	3	5	4	10
		-of which MSM	5	2	2	1	3	1	2	0	0	2
		Female	5	0	3	1	2	8	5	4	5	4
		<b>Total</b>	<b>18</b>	<b>9</b>	<b>8</b>	<b>14</b>	<b>8</b>	<b>12</b>	<b>8</b>	<b>9</b>	<b>9</b>	<b>14</b>
C10CP	Oral labial herpes (culture positive)	Male (all)	4	3	3	3	1	2	3	4	0	3
		-of which MSM	1	0	1	1	0	1	2	1	0	0
		Female	0	2	0	0	2	1	2	3	1	3
		<b>Total</b>	<b>4</b>	<b>5</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>5</b>	<b>7</b>	<b>1</b>	<b>6</b>
C11A	Genital warts, first occurrence	Male (all)	2,842	2,852	2,828	2,878	2,971	3,013	3,107	3,390	3,454	3,718
		-of which MSM	140	128	152	148	139	185	210	265	232	258
		Female	2,487	2,514	2,554	2,412	2,596	2,589	2,687	2,878	2,997	3,173
		<b>Total</b>	<b>5,329</b>	<b>5,366</b>	<b>5,382</b>	<b>5,290</b>	<b>5,567</b>	<b>5,602</b>	<b>5,794</b>	<b>6,268</b>	<b>6,451</b>	<b>6,891</b>
C11B	Genital warts, recurrence	Male (all)	1,272	1,441	1,468	1,526	1,540	1,460	1,538	1,660	1,767	1,859
		-of which MSM	78	76	78	92	77	84	107	148	151	146
		Female	712	841	852	910	950	863	976	1,038	1,021	1,112
		<b>Total</b>	<b>1,984</b>	<b>2,282</b>	<b>2,320</b>	<b>2,436</b>	<b>2,490</b>	<b>2,323</b>	<b>2,514</b>	<b>2,698</b>	<b>2,788</b>	<b>2,971</b>
C11C	Genital warts, reregistered cases	Male (all)	516	751	628	511	403	366	289	277	345	507
		-of which MSM	33	59	51	40	21	32	28	19	37	67
		Female	492	616	568	436	382	302	239	284	270	426
		<b>Total</b>	<b>1,008</b>	<b>1,367</b>	<b>1,196</b>	<b>947</b>	<b>785</b>	<b>668</b>	<b>528</b>	<b>561</b>	<b>615</b>	<b>933</b>
C12	Molluscum contagiosum	Male (all)	187	192	243	266	245	269	340	379	488	556
		-of which MSM	15	18	19	14	11	15	16	20	29	29
		Female	100	145	136	123	143	130	163	193	238	233
		<b>Total</b>	<b>287</b>	<b>337</b>	<b>379</b>	<b>389</b>	<b>388</b>	<b>399</b>	<b>503</b>	<b>572</b>	<b>726</b>	<b>789</b>
C13A	Hepatitis A	Male (all)	3	1	1	1	8	4	1	1	1	10
		-of which MSM	2	0	0	0	2	3	0	1	1	6
		Female	0	0	0	1	6	0	0	0	0	4
		<b>Total</b>	<b>3</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>14</b>	<b>4</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>14</b>
C13B1	Acute Hepatitis B	Male (all)	9	7	14	7	8	5	6	8	8	10
		-of which MSM	4	4	4	4	2	3	3	4	4	3
		Female	0	2	6	2	1	3	2	2	0	4
		<b>Total</b>	<b>9</b>	<b>9</b>	<b>20</b>	<b>9</b>	<b>9</b>	<b>8</b>	<b>8</b>	<b>10</b>	<b>8</b>	<b>14</b>
C13B2	Chronic Hepatitis (HepBsAg + ve > 6 months) - first diagnosis	Male (all)	16	17	13	8	17	6	16	22	9	15
		-of which MSM	2	1	3	1	5	0	6	11	2	0
		Female	2	3	6	4	5	8	4	5	3	3
		<b>Total</b>	<b>18</b>	<b>20</b>	<b>19</b>	<b>12</b>	<b>22</b>	<b>14</b>	<b>20</b>	<b>27</b>	<b>12</b>	<b>18</b>
C13C	Hepatitis C	Male (all)	74	128	122	86	75	80	78	67	24	24
		-of which MSM	4	5	2	2	2	4	4	11	4	4
		Female	70	72	65	39	31	36	37	39	11	10
		<b>Total</b>	<b>144</b>	<b>200</b>	<b>187</b>	<b>125</b>	<b>106</b>	<b>116</b>	<b>115</b>	<b>106</b>	<b>35</b>	<b>34</b>

Scotland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
C13CR	Hepatitis C antibody positive - first diagnoses, PCR confirmed	Male (all)	-	-	-	-	-	-	-	34	50	53
		-of which MSM	-	-	-	-	-	-	-	1	6	9
		Female	-	-	-	-	-	-	-	17	34	19
		<b>Total</b>	-	-	-	-	-	-	-	<b>51</b>	<b>84</b>	<b>72</b>
C13D	Other viral hepatitis	Male (all)	0	2	2	0	0	1	0	1	0	1
		-of which MSM	0	0	1	0	0	0	0	0	0	0
		Female	0	0	0	0	1	1	0	0	0	1
		<b>Total</b>	<b>0</b>	<b>2</b>	<b>2</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>2</b>
C14	Enteric infections/infestations	Male (all)	11	6	4	1	3	6	0	0	3	4
		-of which MSM	9	4	3	1	3	4	0	0	2	4
		Female	0	1	0	1	0	0	0	0	0	1
		<b>Total</b>	<b>11</b>	<b>7</b>	<b>4</b>	<b>2</b>	<b>3</b>	<b>6</b>	<b>0</b>	<b>0</b>	<b>3</b>	<b>5</b>
E1A	Asymptomatic HIV - infection - first presentation	Male (all)	31	39	40	28	22	28	35	78	61	65
		-of which MSM	18	29	18	13	15	15	20	58	43	48
		Female	6	14	11	6	8	19	17	33	11	13
		<b>Total</b>	<b>37</b>	<b>53</b>	<b>51</b>	<b>34</b>	<b>30</b>	<b>47</b>	<b>52</b>	<b>111</b>	<b>72</b>	<b>78</b>
E1B	Asymptomatic HIV - infection - subsequent presentation	Male (all)	564	597	739	308	149	89	155	562	647	685
		-of which MSM	423	490	557	122	76	47	84	404	511	529
		Female	114	129	146	94	33	31	50	193	161	234
		<b>Total</b>	<b>678</b>	<b>726</b>	<b>885</b>	<b>402</b>	<b>182</b>	<b>120</b>	<b>205</b>	<b>755</b>	<b>808</b>	<b>919</b>
E2A	Symptomatic HIV infection (NOT AIDS) - first presentation	Male (all)	24	24	19	8	4	3	7	9	12	20
		-of which MSM	18	22	12	2	2	2	6	8	8	14
		Female	6	9	2	2	0	0	0	3	1	2
		<b>Total</b>	<b>30</b>	<b>33</b>	<b>21</b>	<b>10</b>	<b>4</b>	<b>3</b>	<b>7</b>	<b>12</b>	<b>13</b>	<b>22</b>
E2B	Symptomatic HIV infection (NOT AIDS) - subsequent presentation	Male (all)	766	688	722	300	36	15	54	419	502	467
		-of which MSM	565	508	521	104	7	8	38	328	405	357
		Female	148	168	169	94	16	5	8	102	79	76
		<b>Total</b>	<b>914</b>	<b>856</b>	<b>891</b>	<b>394</b>	<b>52</b>	<b>20</b>	<b>62</b>	<b>521</b>	<b>581</b>	<b>543</b>
E3A	AIDS - first presentation	Male (all)	17	5	15	7	0	3	1	3	5	7
		-of which MSM	7	2	7	4	0	1	0	3	1	4
		Female	2	4	1	1	0	0	0	2	0	2
		<b>Total</b>	<b>19</b>	<b>9</b>	<b>16</b>	<b>8</b>	<b>0</b>	<b>3</b>	<b>1</b>	<b>5</b>	<b>5</b>	<b>9</b>
E3B	AIDS - subsequent presentation	Male (all)	371	354	417	225	29	12	21	125	158	234
		-of which MSM	238	247	291	87	21	8	13	81	106	152
		Female	64	85	77	52	34	6	3	47	35	48
		<b>Total</b>	<b>435</b>	<b>439</b>	<b>494</b>	<b>277</b>	<b>63</b>	<b>18</b>	<b>24</b>	<b>172</b>	<b>193</b>	<b>282</b>
EA	Known HIV - first presentation to this unit	Male (all)	-	-	-	-	-	-	-	19	83	76
		-of which MSM	-	-	-	-	-	-	-	11	59	49
		Female	-	-	-	-	-	-	-	7	18	23
		<b>Total</b>	-	-	-	-	-	-	-	<b>26</b>	<b>101</b>	<b>99</b>

Scotland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
EB	Known HIV - subsequent presentation to this unit	Male (all)	-	-	-	-	-	-	-	46	185	230
		-of which MSM	-	-	-	-	-	-	-	22	145	162
		Female	-	-	-	-	-	-	-	13	41	73
		<b>Total</b>	-	-	-	-	-	-	-	<b>59</b>	<b>226</b>	<b>303</b>
EP	First ever positive HIV test - used only once in a lifetime	Male (all)	-	-	-	-	-	-	-	1	94	70
		-of which MSM	-	-	-	-	-	-	-	1	75	53
		Female	-	-	-	-	-	-	-	1	17	18
		<b>Total</b>	-	-	-	-	-	-	-	<b>2</b>	<b>111</b>	<b>88</b>
D1	Other treponemal diseases	Male (all)	2	0	0	1	2	3	1	3	0	0
		-of which MSM	0	0	0	0	0	1	1	2	0	0
		Female	0	2	0	0	0	0	0	1	2	1
		<b>Total</b>	<b>2</b>	<b>2</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>1</b>	<b>4</b>	<b>2</b>	<b>1</b>
D21	Other conditions requiring treatment - Dermatological	Male (all)	891	996	903	926	922	981	1,137	1,295	1,372	1,520
		-of which MSM	120	147	144	151	144	141	145	190	221	227
		Female	460	432	417	438	475	570	695	802	854	936
		<b>Total</b>	<b>1,351</b>	<b>1,428</b>	<b>1,320</b>	<b>1,364</b>	<b>1,397</b>	<b>1,551</b>	<b>1,832</b>	<b>2,097</b>	<b>2,226</b>	<b>2,456</b>
D22	Other conditions requiring treatment - Gynaecological	Male (all)	0	0	0	0	0	0	0	0	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	192	159	70	73	59	62	57	66	90	90
		<b>Total</b>	<b>192</b>	<b>159</b>	<b>70</b>	<b>73</b>	<b>59</b>	<b>62</b>	<b>57</b>	<b>66</b>	<b>90</b>	<b>90</b>
D23	Other conditions requiring treatment - Contraception	Male (all)	136	154	158	121	296	289	289	27	0	0
		-of which MSM	0	2	5	2	1	11	14	0	0	0
		Female	344	384	496	376	599	728	784	159	0	0
		<b>Total</b>	<b>480</b>	<b>538</b>	<b>654</b>	<b>497</b>	<b>895</b>	<b>1,017</b>	<b>1,073</b>	<b>186</b>	<b>0</b>	<b>0</b>
D24	Other conditions requiring treatment - Trauma/foreign body	Male (all)	16	21	24	21	35	40	25	9	12	18
		-of which MSM	2	2	5	3	1	0	1	2	7	2
		Female	13	21	18	18	22	33	19	10	5	15
		<b>Total</b>	<b>29</b>	<b>42</b>	<b>42</b>	<b>39</b>	<b>57</b>	<b>73</b>	<b>44</b>	<b>19</b>	<b>17</b>	<b>33</b>
D25	Other conditions requiring treatment - Minor surgery/excision biopsy	Male (all)	19	31	35	24	24	52	47	73	63	53
		-of which MSM	2	7	6	5	4	6	3	9	10	7
		Female	11	23	43	36	28	56	78	95	64	68
		<b>Total</b>	<b>30</b>	<b>54</b>	<b>78</b>	<b>60</b>	<b>52</b>	<b>108</b>	<b>125</b>	<b>168</b>	<b>127</b>	<b>121</b>
D26	Other conditions requiring treatment - Colposcopy (treatment required)	Male (all)	0	0	0	0	0	0	0	0	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	22	39	19	19	12	7	15	14	2	1
		<b>Total</b>	<b>22</b>	<b>39</b>	<b>19</b>	<b>19</b>	<b>12</b>	<b>7</b>	<b>15</b>	<b>14</b>	<b>2</b>	<b>1</b>
D27	Other conditions requiring treatment - Vaccination	Male (all)	771	977	1,022	785	676	1,081	1,441	347	0	0
		-of which MSM	607	815	797	571	482	787	1,005	206	0	0
		Female	133	203	294	163	129	221	261	75	0	0
		<b>Total</b>	<b>904</b>	<b>1,180</b>	<b>1,316</b>	<b>948</b>	<b>805</b>	<b>1,302</b>	<b>1,702</b>	<b>422</b>	<b>0</b>	<b>0</b>

Scotland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
D28	Other conditions requiring treatment - Other conditions	Male (all)	407	527	456	432	433	511	397	490	445	517
		-of which MSM	56	61	62	62	44	69	70	93	139	126
		Female	294	506	491	410	322	381	402	481	451	415
		<b>Total</b>	<b>701</b>	<b>1,033</b>	<b>947</b>	<b>842</b>	<b>755</b>	<b>892</b>	<b>799</b>	<b>971</b>	<b>896</b>	<b>932</b>
D31	STD screen negative	Male (all)	3,658	4,293	4,616	4,730	6,119	7,464	9,188	11,566	0	0
		-of which MSM	498	530	685	564	736	986	1,077	1,470	0	0
		Female	2,729	2,899	3,548	3,341	4,528	5,959	7,508	9,315	0	0
		<b>Total</b>	<b>6,387</b>	<b>7,192</b>	<b>8,164</b>	<b>8,071</b>	<b>10,647</b>	<b>13,423</b>	<b>16,696</b>	<b>20,881</b>	<b>0</b>	<b>0</b>
D32N	HIV counselling - result negative	Male (all)	3,195	3,453	3,827	3,874	4,774	6,791	8,946	13,175	0	0
		-of which MSM	708	740	901	857	976	1,270	1,532	2,011	0	0
		Female	2,146	2,348	2,593	2,463	3,188	4,927	6,783	10,089	0	0
		<b>Total</b>	<b>5,341</b>	<b>5,801</b>	<b>6,420</b>	<b>6,337</b>	<b>7,962</b>	<b>11,718</b>	<b>15,729</b>	<b>23,264</b>	<b>0</b>	<b>0</b>
D32P	HIV counselling - result positive	Male (all)	32	35	49	20	35	37	35	78	0	0
		-of which MSM	17	29	24	8	13	19	23	56	0	0
		Female	8	19	15	16	12	13	13	30	0	0
		<b>Total</b>	<b>40</b>	<b>54</b>	<b>64</b>	<b>36</b>	<b>47</b>	<b>50</b>	<b>48</b>	<b>108</b>	<b>0</b>	<b>0</b>
D32Z	HIV counselling - test not done	Male (all)	414	439	448	433	334	717	1,841	6,504	0	0
		-of which MSM	32	45	72	44	24	45	67	594	0	0
		Female	292	313	341	289	293	596	1,786	5,639	0	0
		<b>Total</b>	<b>706</b>	<b>752</b>	<b>789</b>	<b>722</b>	<b>627</b>	<b>1,313</b>	<b>3,627</b>	<b>12,143</b>	<b>0</b>	<b>0</b>
D33	Psychosexual counselling	Male (all)	69	120	154	132	118	76	68	104	63	64
		-of which MSM	12	37	38	39	27	16	16	29	11	4
		Female	41	42	42	33	25	32	30	39	44	45
		<b>Total</b>	<b>110</b>	<b>162</b>	<b>196</b>	<b>165</b>	<b>143</b>	<b>108</b>	<b>98</b>	<b>143</b>	<b>107</b>	<b>109</b>
D34	Sexual assault support	Male (all)	16	16	19	13	4	4	5	5	0	0
		-of which MSM	7	11	8	5	1	0	0	0	0	0
		Female	145	90	101	58	37	49	72	23	0	0
		<b>Total</b>	<b>161</b>	<b>106</b>	<b>120</b>	<b>71</b>	<b>41</b>	<b>53</b>	<b>77</b>	<b>28</b>	<b>0</b>	<b>0</b>
D34A	Sexual assault support - recent	Male (all)	2	9	11	24	22	30	43	45	76	64
		-of which MSM	2	7	5	13	10	21	13	20	39	38
		Female	46	101	109	119	167	248	285	408	476	509
		<b>Total</b>	<b>48</b>	<b>110</b>	<b>120</b>	<b>143</b>	<b>189</b>	<b>278</b>	<b>328</b>	<b>453</b>	<b>552</b>	<b>573</b>
D34B	Sexual assault support - history of	Male (all)	5	40	34	8	15	29	50	76	88	63
		-of which MSM	4	37	27	4	7	6	16	25	50	26
		Female	23	63	96	41	60	207	253	321	285	258
		<b>Total</b>	<b>28</b>	<b>103</b>	<b>130</b>	<b>49</b>	<b>75</b>	<b>236</b>	<b>303</b>	<b>397</b>	<b>373</b>	<b>321</b>
D35	Other counselling	Male (all)	291	568	694	675	504	456	488	376	408	722
		-of which MSM	41	80	99	80	62	70	64	72	69	96
		Female	383	529	719	645	692	613	686	537	468	935
		<b>Total</b>	<b>674</b>	<b>1,097</b>	<b>1,413</b>	<b>1,320</b>	<b>1,196</b>	<b>1,069</b>	<b>1,174</b>	<b>913</b>	<b>876</b>	<b>1,657</b>

Scotland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
D36	Colposcopy (no treatment required)	Male (all)	0	0	0	0	0	0	0	0	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	42	29	11	15	0	2	3	15	3	0
		<b>Total</b>	<b>42</b>	<b>29</b>	<b>11</b>	<b>15</b>	<b>0</b>	<b>2</b>	<b>3</b>	<b>15</b>	<b>3</b>	<b>0</b>
D37	Other conditions	Male (all)	532	596	791	522	749	1,301	1,338	1,847	263	232
		-of which MSM	64	96	160	97	111	207	230	281	44	42
		Female	676	832	1,017	708	931	1,191	1,083	1,430	247	271
		<b>Total</b>	<b>1,208</b>	<b>1,428</b>	<b>1,808</b>	<b>1,230</b>	<b>1,680</b>	<b>2,492</b>	<b>2,421</b>	<b>3,277</b>	<b>510</b>	<b>503</b>
D38AN	Non-occupational HIV post-exposure prophylaxis - advice only	Male (all)	-	-	-	-	-	-	-	4	14	10
		-of which MSM	-	-	-	-	-	-	-	1	4	0
		Female	-	-	-	-	-	-	-	0	7	7
		<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>4</b>	<b>21</b>	<b>17</b>
D38AO	Occupational HIV post-exposure prophylaxis - advice only	Male (all)	-	-	-	-	-	-	-	13	24	19
		-of which MSM	-	-	-	-	-	-	-	0	0	0
		Female	-	-	-	-	-	-	-	14	24	14
		<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>27</b>	<b>48</b>	<b>33</b>
D38BN	Non-occupational HIV post-exposure prophylaxis - treatment initiated	Male (all)	-	-	-	-	-	-	-	8	20	36
		-of which MSM	-	-	-	-	-	-	-	6	12	27
		Female	-	-	-	-	-	-	-	7	9	10
		<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>15</b>	<b>29</b>	<b>46</b>
D38BO	Occupational HIV post-exposure prophylaxis - treatment initiated	Male (all)	-	-	-	-	-	-	-	3	3	5
		-of which MSM	-	-	-	-	-	-	-	0	0	1
		Female	-	-	-	-	-	-	-	7	5	10
		<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>10</b>	<b>8</b>	<b>15</b>
D41	Referral to Dermatology	Male (all)	19	34	37	36	47	41	52	81	74	68
		-of which MSM	2	3	4	3	8	9	4	15	18	10
		Female	24	19	30	23	31	21	20	33	26	29
		<b>Total</b>	<b>43</b>	<b>53</b>	<b>67</b>	<b>59</b>	<b>78</b>	<b>62</b>	<b>72</b>	<b>114</b>	<b>100</b>	<b>97</b>
D42	Referral to Gynaecology	Male (all)	0	0	0	0	0	0	0	1	0	0
		-of which MSM	0	0	0	0	0	0	0	1	0	0
		Female	119	149	157	137	136	126	95	135	176	134
		<b>Total</b>	<b>119</b>	<b>149</b>	<b>157</b>	<b>137</b>	<b>136</b>	<b>126</b>	<b>95</b>	<b>136</b>	<b>176</b>	<b>134</b>
D43	Referral to termination of pregnancy	Male (all)	0	0	0	0	0	0	0	0	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	19	20	33	27	36	40	50	41	64	55
		<b>Total</b>	<b>19</b>	<b>20</b>	<b>33</b>	<b>27</b>	<b>36</b>	<b>40</b>	<b>50</b>	<b>41</b>	<b>64</b>	<b>55</b>
D44	Referral to Psychology/Psychiatry	Male (all)	22	34	23	43	44	44	60	49	57	90
		-of which MSM	11	12	7	12	12	15	8	9	20	25
		Female	16	8	6	15	10	29	28	36	20	33
		<b>Total</b>	<b>38</b>	<b>42</b>	<b>29</b>	<b>58</b>	<b>54</b>	<b>73</b>	<b>88</b>	<b>85</b>	<b>77</b>	<b>123</b>

Scotland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
D45	Referral to Surgery (including Urology)	Male (all)	225	248	243	216	232	177	251	255	254	210
		-of which MSM	28	36	29	20	19	14	29	28	47	46
		Female	27	27	34	24	25	15	22	26	25	19
		<b>Total</b>	<b>252</b>	<b>275</b>	<b>277</b>	<b>240</b>	<b>257</b>	<b>192</b>	<b>273</b>	<b>281</b>	<b>279</b>	<b>229</b>
D46	Referral for genital carcinoma	Male (all)	0	2	0	2	2	0	0	1	1	3
		-of which MSM	0	0	0	1	0	0	0	0	0	2
		Female	2	0	1	2	1	0	1	1	0	1
		<b>Total</b>	<b>2</b>	<b>2</b>	<b>1</b>	<b>4</b>	<b>3</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>4</b>
D47	Referral for colposcopy	Male (all)	0	0	0	0	0	0	0	0	0	0
		-of which MSM	0	0	0	0	0	0	0	0	0	0
		Female	109	102	99	72	98	89	140	106	122	103
		<b>Total</b>	<b>109</b>	<b>102</b>	<b>99</b>	<b>72</b>	<b>98</b>	<b>89</b>	<b>140</b>	<b>106</b>	<b>122</b>	<b>103</b>
D48	Referral for other conditions	Male (all)	100	146	120	111	133	129	138	204	212	229
		-of which MSM	21	26	17	12	14	13	21	46	84	81
		Female	92	132	123	65	79	95	97	100	100	86
		<b>Total</b>	<b>192</b>	<b>278</b>	<b>243</b>	<b>176</b>	<b>212</b>	<b>224</b>	<b>235</b>	<b>304</b>	<b>312</b>	<b>315</b>
F0	Contraceptive advice only - no supplies issued	Male (all)	-	-	-	-	-	-	-	12	82	156
		-of which MSM	-	-	-	-	-	-	-	2	41	35
		Female	-	-	-	-	-	-	-	110	311	652
		<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>122</b>	<b>393</b>	<b>808</b>
F1D	Initiation or re-supply of injectable contraception	Male (all)	-	-	-	-	-	-	-	0	0	0
		-of which MSM	-	-	-	-	-	-	-	0	0	0
		Female	-	-	-	-	-	-	-	39	52	65
		<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>39</b>	<b>52</b>	<b>65</b>
F1E	Emergency contraception	Male (all)	-	-	-	-	-	-	-	0	0	0
		-of which MSM	-	-	-	-	-	-	-	0	0	0
		Female	-	-	-	-	-	-	-	198	307	402
		<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>198</b>	<b>307</b>	<b>402</b>
F1O	Initiation or re-supply of oral contraception	Male (all)	-	-	-	-	-	-	-	0	0	0
		-of which MSM	-	-	-	-	-	-	-	0	0	0
		Female	-	-	-	-	-	-	-	95	155	227
		<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>95</b>	<b>155</b>	<b>227</b>
F2	IUD/IUS/implant	Male (all)	-	-	-	-	-	-	-	0	0	0
		-of which MSM	-	-	-	-	-	-	-	0	0	0
		Female	-	-	-	-	-	-	-	45	82	71
		<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>45</b>	<b>82</b>	<b>71</b>
F3	Condoms supplied	Male (all)	-	-	-	-	-	-	-	649	2,300	3,806
		-of which MSM	-	-	-	-	-	-	-	71	274	356
		Female	-	-	-	-	-	-	-	714	2,206	3,446
		<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,363</b>	<b>4,506</b>	<b>7,252</b>

Scotland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	
S0	Consultation without STI screen: HIV test not offered	Male (all)	-	-	-	-	-	-	-	-	5,258	5,367	
		-of which MSM	-	-	-	-	-	-	-	-	1,985	1,858	
		Female	-	-	-	-	-	-	-	-	4,060	4,523	
		<b>Total</b>	-	-	-	-	-	-	-	-	<b>9,318</b>	<b>9,890</b>	
S0D	Consultation without STI screen: HIV test deferred/declined	Male (all)	-	-	-	-	-	-	-	-	1,339	1,532	
		-of which MSM	-	-	-	-	-	-	-	-	97	139	
		Female	-	-	-	-	-	-	-	-	1,314	1,544	
		<b>Total</b>	-	-	-	-	-	-	-	-	<b>2,653</b>	<b>3,076</b>	
S0H	Consultation without STI screen: HIV test done	Male (all)	-	-	-	-	-	-	-	-	1,321	1,281	
		-of which MSM	-	-	-	-	-	-	-	-	371	377	
		Female	-	-	-	-	-	-	-	-	1,135	1,066	
		<b>Total</b>	-	-	-	-	-	-	-	-	<b>2,456</b>	<b>2,347</b>	
S1	STI screen: HIV test not offered	Male (all)	-	-	-	-	-	-	-	-	2,502	2,982	
		-of which MSM	-	-	-	-	-	-	-	-	395	429	
		Female	-	-	-	-	-	-	-	-	2,360	4,098	
		<b>Total</b>	-	-	-	-	-	-	-	-	<b>4,862</b>	<b>7,080</b>	
S1D	STI screen: HIV test deferred/declined	Male (all)	-	-	-	-	-	-	-	-	8,007	8,144	
		-of which MSM	-	-	-	-	-	-	-	-	679	655	
		Female	-	-	-	-	-	-	-	-	7,781	7,616	
		<b>Total</b>	-	-	-	-	-	-	-	-	<b>15,788</b>	<b>15,760</b>	
S1H	STI screen: HIV test done	Male (all)	-	-	-	-	-	-	-	-	16,394	18,674	
		-of which MSM	-	-	-	-	-	-	-	-	2,332	2,793	
		Female	-	-	-	-	-	-	-	-	12,941	14,237	
		<b>Total</b>	-	-	-	-	-	-	-	-	<b>29,335</b>	<b>32,911</b>	
V1A	Hepatitis A - first dose of new course	Male (all)	-	-	-	-	-	-	-	35	65	55	
		-of which MSM	-	-	-	-	-	-	-	26	53	47	
		Female	-	-	-	-	-	-	-	-	7	8	7
		<b>Total</b>	-	-	-	-	-	-	-	-	<b>42</b>	<b>73</b>	<b>62</b>
V1AB	Combined hepatitis A+B - first dose	Male (all)	-	-	-	-	-	-	-	481	711	724	
		-of which MSM	-	-	-	-	-	-	-	381	624	649	
		Female	-	-	-	-	-	-	-	-	39	51	46
		<b>Total</b>	-	-	-	-	-	-	-	-	<b>520</b>	<b>762</b>	<b>770</b>
V1B	Hepatitis B - first dose of new course	Male (all)	-	-	-	-	-	-	-	285	399	404	
		-of which MSM	-	-	-	-	-	-	-	166	235	250	
		Female	-	-	-	-	-	-	-	-	120	217	226
		<b>Total</b>	-	-	-	-	-	-	-	-	<b>405</b>	<b>616</b>	<b>630</b>
V1C	Other vaccination - first dose	Male (all)	-	-	-	-	-	-	-	14	28	20	
		-of which MSM	-	-	-	-	-	-	-	6	11	11	
		Female	-	-	-	-	-	-	-	-	9	14	10
		<b>Total</b>	-	-	-	-	-	-	-	-	<b>23</b>	<b>42</b>	<b>30</b>

Scotland: Number of new episodes by sex, 1997 - 2006 continued			1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
V2A	Hepatitis A - all subsequent doses	Male (all)	-	-	-	-	-	-	-	13	31	27
		-of which MSM	-	-	-	-	-	-	-	10	27	22
		Female	-	-	-	-	-	-	-	2	0	2
		<b>Total</b>	-	-	-	-	-	-	-	<b>15</b>	<b>31</b>	<b>29</b>
V2AB	Combined hepatitis A+B - all subsequent doses	Male (all)	-	-	-	-	-	-	-	513	765	862
		-of which MSM	-	-	-	-	-	-	-	402	693	785
		Female	-	-	-	-	-	-	-	31	35	51
		<b>Total</b>	-	-	-	-	-	-	-	<b>544</b>	<b>800</b>	<b>913</b>
V2B	Hepatitis B - all subsequent doses	Male (all)	-	-	-	-	-	-	-	505	736	783
		-of which MSM	-	-	-	-	-	-	-	332	501	586
		Female	-	-	-	-	-	-	-	133	277	325
		<b>Total</b>	-	-	-	-	-	-	-	<b>638</b>	<b>1,013</b>	<b>1,108</b>
V2C	Other vaccination - all subsequent doses	Male (all)	-	-	-	-	-	-	-	1	3	1
		-of which MSM	-	-	-	-	-	-	-	1	2	0
		Female	-	-	-	-	-	-	-	1	2	1
		<b>Total</b>	-	-	-	-	-	-	-	<b>2</b>	<b>5</b>	<b>2</b>
<b>Total new STI diagnoses</b>		Male (all)	6,897	6,911	7,513	7,850	8,566	9,154	9,942	10,968	11,663	12,357
		-of which MSM	589	535	641	759	757	974	1,203	1,447	1,576	1,770
		Female	4,861	5,245	5,761	5,611	6,687	7,022	7,442	7,853	8,670	9,261
		<b>Total</b>	<b>11,758</b>	<b>12,156</b>	<b>13,274</b>	<b>13,461</b>	<b>15,253</b>	<b>16,176</b>	<b>17,384</b>	<b>18,821</b>	<b>20,333</b>	<b>21,618</b>
<b>Total other STI diagnoses</b>		Male (all)	4,396	4,867	5,163	4,259	3,935	4,000	4,416	5,686	6,376	7,075
		-of which MSM	1,410	1,439	1,564	557	335	377	601	1,393	1,827	1,953
		Female	2,427	2,759	2,809	2,574	2,728	2,695	2,830	3,393	3,483	4,018
		<b>Total</b>	<b>6,823</b>	<b>7,626</b>	<b>7,972</b>	<b>6,833</b>	<b>6,663</b>	<b>6,695</b>	<b>7,246</b>	<b>9,079</b>	<b>9,859</b>	<b>11,093</b>
<b>Total other GUM clinic diagnoses</b>		Male (all)	3,503	3,964	3,879	3,555	3,681	4,228	4,662	3,735	3,295	3,659
		-of which MSM	873	1,114	1,107	858	769	1,103	1,341	609	484	507
		Female	4,381	4,795	4,926	4,757	5,176	6,052	6,497	6,257	6,367	6,532
		<b>Total</b>	<b>7,884</b>	<b>8,759</b>	<b>8,805</b>	<b>8,312</b>	<b>8,857</b>	<b>10,280</b>	<b>11,159</b>	<b>9,992</b>	<b>9,662</b>	<b>10,191</b>
<b>Total services provided</b>		Male (all)	8,672	10,200	11,240	10,969	13,267	17,435	22,682	37,166	41,888	47,066
		-of which MSM	1,459	1,707	2,110	1,783	2,056	2,733	3,178	6,227	9,052	9,749
		Female	7,015	7,804	9,142	8,145	10,395	14,305	19,014	29,953	35,433	41,163
		<b>Total</b>	<b>15,687</b>	<b>18,004</b>	<b>20,382</b>	<b>19,114</b>	<b>23,662</b>	<b>31,740</b>	<b>41,696</b>	<b>67,119</b>	<b>77,321</b>	<b>88,229</b>

Source: HPA Centre for Infections

\* previous diagnosis of C11a or C11b treated for more than 3 months

† KC60 codes were created/revised in quarter 3, 2002

- data not available/applicable

**Supplementary Tables of Sexually Transmitted Infections in the United Kingdom**



<b>Code Groups</b>
<b>New STI Diagnoses</b>
Chlamydial infection (uncomplicated and complicated)
Gonorrhoea (uncomplicated and complicated)
Infectious syphilis
Genital Herpes simplex (first attack)
Genital warts (first attack)
New HIV diagnosis
Non-specific genital infection (uncomplicated and complicated)
Chancroid/lymphogranuloma venerum (LGV)/Donovanosis
Molluscum contagiosum
Trichomoniasis
Scabies
Pediculus pubis
<b>Other STI Diagnoses</b>
Early latent, congenital and other acquired syphilis
Recurrent genital Herpes simplex
Recurrent and re-registered genital warts
Subsequent HIV presentations (including AIDS)
Ophthalmia neonatorum (chlamydial or gonococcal)
Epidemiological treatment of suspected STIs (syphilis, chlamydia, gonorrhoea, non-specific genital infection)
<b>Other diagnoses made at GUM clinics</b>
Viral hepatitis B
Viral hepatitis C
Vaginosis and balanitis (including epidemiological treatment)
Anogenital candidiasis (including epidemiological treatment)
Urinary tract infection
Cervical abnormalities
Other conditions requiring treatment at a GUM clinic
<b>Services provided</b>
HIV antibody test
Sexual health screen
Hepatitis B vaccination
Contraception (excluding condom provision)
Other episode not requiring treatment